

Indiana Medicaid Statewide Uniform Preferred Drug List (SUPDL)

Optum Rx Call Center

For prior authorization requests, claims processing issues or questions about the SUPDL, please contact Optum Rx at 855-577-6317

Or fax the prior authorization requests to 855-577-6384

Indiana Health Coverage Programs (IHCP) Drug Coverage

In accordance with 405 IAC 5-24, the IHCP covers all FDA-approved legend drugs with the exception of the following:

- Drugs designated by Centers for Medicare and Medicaid Services (CMS, formerly HCFA) as “less than effective” (DESI), or identical, related, or similar to a DESI drug
- Anorectics or any agent used to promote weight loss
- Topical minoxidil preparations
- Fertility enhancement drugs
- Drugs used primarily or solely for cosmetic purposes

Note: Inclusion of, or reference to, any given drug does not indicate market availability of the drug. Drugs that will be or have been withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

Nomenclature

- **Statewide Uniform Preferred Drug List (SUPDL)** - a list of drugs within select therapeutic drug classes, developed and maintained by the Drug Utilization Review (DUR) Board, designated as *preferred* or *non-preferred* based upon clinical and financial considerations.
 - **Preferred Drug** – Covered drug designated by the DUR Board as a principle agent for use within a therapeutic class.
 - **Non-preferred Drug** – Covered drug designated by the DUR Board as secondary agent for use within a therapeutic class. Non-preferred drugs typically require prior authorization and history of trial and failure of (each of) the preferred agent(s), as confirmed by claims history, chart documentation, or provider attestation including dates of trial for each preferred agent (unless otherwise specified on the SUPDL).
 - Legacy continuation of therapy - The process whereby criteria are established exempting a drug from prior authorization, under specific conditions, when it would otherwise require prior authorization.
 - Brand name drugs, with an available generic, authorized generic, or authorized brand alternative, are *non-preferred* unless otherwise specified on the SUPDL and the Preferred Brand Drug List. All brand products on the SUPDL with a new available generic, authorized generic, or authorized brand alternative will list the newly released agent as the same status as the brand product until reviewed by the Drug Utilization Review Board for inclusion on the Preferred Brand Drug List. Position of the brand product and its corresponding generic, authorized generic, or authorized brand alternative can then be switched based on financial advantage.

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

- Prior authorization is typically required for a prescriber's specification of "brand medically necessary" or "generic medically necessary".
- Certain drugs, sometimes referred to as "narrow therapeutic index" drugs, are exempt from the requirement of prior authorization for "brand medically necessary"; see information in the [Pharmacy Services Provider Module](#).
- **Neutral Drug** – Covered drug that is in a therapeutic class not included on the SUPDL. As such, the drug has neither *preferred* nor *non-preferred* status.
- **Line Extension Drug** – A new strength, formulation, or dosage form of a particular chemical entity for a given manufacturer that has been approved by the FDA. The SUPDL status of a line extension drug is the same as the status of the chemical entity to which it pertains unless otherwise determined by the DUR Board.
- **Point of Sale Quick Check (PSQC)** – real-time automated prior authorization system that utilizes clinical prior authorization edits supported by a member's medical and pharmacy claims data. This process results in quicker PA determination for pharmacy claims processed by the fee-for-service (FFS) pharmacy benefit, with less intervention on the part of the pharmacy and prescribing providers.
- **Status Pending Drug** – Covered drug that is subject to the SUPDL, but for which *preferred* or *non-preferred* status has yet to be assigned.

Prior Authorization (PA)

This term is defined at 405 IAC 5-2-20. Any IHCP covered legend drug (including drugs that are or are not listed on the SUPDL) may require PA. Prior authorization is generally required in order to ensure appropriate drug utilization, conformance to established therapeutic guidelines, and fiscal reasonability.

Prior authorization request forms are located at <https://www.in.gov/medicaid/providers/index.html> under Pharmacy Services. Select "[PA Criteria and Administrative Forms](#)" under the "Quick Links" column on the right-hand margin. Drug specific PA criteria are attached to each associated drug class within the SUPDL document. Non-specific criteria are located at the end of the SUPDL document.

Indiana Medicaid Statewide Uniform Preferred Drug List Table of Contents

Indiana Health Coverage Programs	Angiotensin Receptor Blocker Combinations.....	Smoking Deterrent Agents.....
(IHCP) Drug Coverage..... 1	Beta Adrenergic Blockers 14	DERMATOLOGIC.....34
Nomenclature 1	Beta Adrenergic Blockers with Diuretics 14	Acne Agents 34
Prior Authorization (PA) 2	Calcium Channel Blockers 15	Antipsoriatics 35
ANTI-INFECTIVES 5	Miscellaneous Cardiac Agents..... 15	ELECTROLYTE DEPLETERS.....36
Antivirals – Anti-Herpetic 5	CNS AND OTHERS 16	Electrolyte Depleters 36
Antivirals – Influenza and 5	Agents for the Treatment of Opioid Use Disorder or	ENDOCRINE 37
COVID-19 5	Overdose 16	Anaphylaxis Agents 37
Cephalosporins – 3 rd Generation..... 5	Antiemetic/Antivertigo Agents 17	Bone Formation Stimulating Agents 37
Fluoroquinolones 5	Antiseizure Agents 19	Bone Resorption Inhibitors 37
Hepatitis C Agents 5	Gastroprotective Agents 20	DPP4 Inhibitors and Combination Agents 38
Macrolides..... 6	Mental Health Agents: Alzheimer’s and Dementia	GLP-1 Receptor Agonists and Combinations..... 39
Ophthalmic Antibiotics 6	Agents 21	Glucagon Agents 40
Ophthalmic Antibiotics/ Corticosteroid	Mental Health Agents: Anti-Anxiety and Related	Growth Hormones 40
Combinations 7	Disorders 22	Insulins – Intermediate Acting 41
Otic Antibiotics 7	Mental Health Agents: Antidepressant Agents 23	Insulins – Rapid Acting 41
Systemic Antifungals 8	Mental Health Agents: Antipsychotic and Antimanic	Insulins – Short Acting 42
Topical Antifungals 9	Agents 25	Insulins – Long Acting 42
Topical Antivirals 9	Mental Health Agents: Insomnia Agents..... 27	Miscellaneous Oral Antidiabetic Agents 42
Vaginal Antimicrobials..... 10	Mental Health Agents: Narcolepsy and Cataplexy	SGLT Inhibitors and Combinations..... 43
ANTIMIGRAINE.....11	Agents 28	Testosterones 44
Antimigraine Preparations 11	Mental Health Agents: Non-Stimulant ADHD Agents	Urea Cycle Disorders (Hyperammonemia
CARDIOVASCULAR.....13	 28	Treatments) 44
ACE Inhibitors 13	Mental Health Agents: Stimulants 29	ESTROGEN AND RELATED AGENTS 45
ACE Inhibitor Combinations 13	Movement Disorder Agents 30	Estrogen and Related Agents 45
Angiotensin Receptor Blockers 13	Narcotic Antitussives and Combinations..... 30	Contraceptives 46
	Narcotics 31	
	Skeletal Muscle Relaxants 32	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

GASTROINTESTINAL AGENTS	47	Lipotropics.....	54	Otic Preparations	64
Anti-ulcer Agents.....	47	MULTIPLE SCLEROSIS AGENTS.....	55	Topical Anti-Inflammatory Agents – NSAIDS	65
<i>H. Pylori</i> Agents	47	Multiple Sclerosis Agents	55	Topical Antiparasitics	65
H2 Receptor Antagonists.....	47	RESPIRATORY	56	Topical Immunomodulators.....	65
Laxatives and Cathartics	48	Antihistamine-Decongestant Combinations/2 nd		Topical Post-Herpetic Neuralgia Agents	65
Pancreatic Enzymes.....	49	Generation Antihistamines	56	MISCELLANEOUS INFORMATION	65
Proton Pump Inhibitors	49	Beta Adrenergics and Corticosteroids.....	57		
Ulcerative Colitis Agents.....	50	Beta Agonists – Long Acting	57		
GENITOURINARY	51	Beta Agonists – Short Acting	58		
BPH Agents.....	51	Bronchodilator Agents-Beta Adrenergic and			
Urinary Tract Antispasmodic/Anti-Incontinence		Anticholinergic Combinations	58		
Agents	51	Leukotriene Receptor Antagonists.....	59		
HEMATOLOGIC.....	52	Nasal Antihistamines/Nasal Anti-Inflammatory			
Direct Oral Anticoagulants	52	Steroids	59		
Hematinics.....	52	Oral Inhaled Glucocorticoids.....	59		
Hemophilia Prophylaxis Agents.....	53	Pulmonary Antihypertensives	60		
Hereditary Angioedema Agents	53	Respiratory and Allergy Biologics.....	60		
Leukocyte Stimulants	53	TARGETED IMMUNOMODULATORS.....	61		
Platelet Aggregation Inhibitors.....	53	Targeted Immunomodulators	61		
LIPOTROPICS	54	TOPICAL AGENTS.....	62		
Bile Acid Sequestrants	54	Dry Eye Disease or Keratoconjunctivitis.....	62		
Fibric Acid Derivatives	54	Miotics-Intraocular Pressure Reducers	63		
HMG CoA Reductase Inhibitors	54	Ophthalmic Antihistamines.....	64		
		Ophthalmic Anti-Inflammatory Agents	64		

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES			
Antivirals – Anti-Herpetic	- acyclovir - valacyclovir - ST – must have diagnosis of HIV or trial and failure of acyclovir or medical justification for use over acyclovir	famciclovir	
Antivirals – Influenza and COVID-19	Influenza - oseltamivir - Relenza COVID-19 - Paxlovid - AGE – 12 years of age and older - QL – 1 therapy pack every 30 days	Influenza - Rapivab - Xofluza COVID-19 - N/A	
Cephalosporins – 3rd Generation	- cefдинир - cefподoxime	cefixime caps, susp	
Fluoroquinolones *Note: All fluoroquinolones will be limited to 14 days per claim*	- ciprofloxacin - levofloxacin - moxifloxacin	- Baxdela - ofloxacin PA criteria must be met for the following: - Cipro suspension - ciprofloxacin suspension - levofloxacin soln	PA Criteria for ciprofloxacin and levofloxacin solution
Hepatitis C Agents	- Pegasys - ribavirin PA criteria must be met for the following (note: treatment naïve patients must only meet age and quantity limits): - Epclusa 200-50mg - Epclusa 150-37.5mg - Mavyret - sofosbuvir/velpatasvir 400-100mg	PA criteria must be met for the following: - Epclusa 400-100mg - Harvoni 45-200 mg tablet; 45-200 mg packet; 33.75 mg-150 mg packet - ledipasvir/sofosbuvir 90-400 mg tablet - Sovaldi - Vosevi	Hepatitis C Agents PA Criteria Hepatitis C Agents PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES - Continued			
Macrolides	• azithromycin suspension 100 mg/5 mL, 200 mg/5 mL • azithromycin 600 mg oral tablets ○ QL – 1 tablet/day • azithromycin 500 mg oral tablets ○ QL – 7 tablets/30 days • azithromycin 250 mg oral tablets ○ QL – 6 tablets/30 days • clarithromycin • erythromycin tablets • erythromycin ethylsuccinate susp ○ ST – must be under 12 years of age or unable to swallow tablets/capsules	• E.E.S. Granules ○ ST – must have tried and failed erythromycin ethylsuccinate suspension in the past 90 days OR member must be under 12 years of age or unable to swallow tablets/capsules and prescriber has provided valid medical justification for the use of E.E.S. Granules over preferred agents • E.E.S. tablets • erythrocin stearate • erythromycin tablets EC PA criteria must be met for the following: • Difacid PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • fidaxomicin	Difacid PA Criteria Difacid PA Form
Ophthalmic Antibiotics	• Azasite soln • Besivance susp • Ciloxan oint • ciprofloxacin soln • erythromycin oint • gentamicin soln • moxifloxacin soln ○ AGE – 30 years of age or older; ST – patients under 30 years of age must have tried at least one preferred agent other than moxifloxacin within the past 30 days • ofloxacin soln • polymyxin B/bacitracin oint • polymyxin B/trimethoprim soln • sulfacet sod oint • tobramycin soln • Tobrex oint	• bacitracin oint • besifloxacin susp • gatifloxacin soln • neomycin/bacitracin/polymyxin oint • neomycin/polymyxin B/gramicidin soln	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES - Continued			
Ophthalmic Antibiotics/ Corticosteroid Combinations	- neomycin/polymyxin B/dexamethasone oint - neomycin/polymyxin B/dexamethasone susp - sulfacetamide sodium/prednisolone soln - Tobradex oint - Tobradex ST susp - tobramycin/dexamethasone susp - Zylet susp	- loteprednol/tobramycin susp - neomycin/polymyxin/bacitracin/hc oint - neomycin/polymyxin/hc susp	
Otic Antibiotics	- ofloxacin otic soln <i>Antibiotic/Steroid Combinations</i> - ciprofloxacin-dexamethasone otic susp - Cipro HC susp - Cortisporin TC otic susp - neomycin/polymyxin B/hydrocortisone otic soln - neomycin/polymyxin B/hydrocortisone otic susp	- ciprofloxacin soln <i>Antibiotic/Steroid Combinations</i> Generic Medically Necessary PA criteria must be met for the following: - ciprofloxacin/hydrocortisone otic susp	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES - Continued			
Systemic Antifungals	- fluconazole 50 mg tabs - QL – 3 tabs/30 days - fluconazole 150 mg tabs - QL – 4 tabs/30 days - fluconazole suspension - itraconazole - ketoconazole - terbinafine	- Cresemba - itraconazole soln - ST – must have tried and failed all preferred agents (i.e., each preferred chemical entity) or must provide medical justification as to why each preferred agent is not appropriate for use (e.g., infection being treated is not susceptible to preferred agents); must be 12 years of age and under OR unable to swallow capsules/tablets - Noxafil PAK - ST – must be 2 years of age or older and less than 13 years of age - posaconazole tablet & 200 mg/5 mL suspension - ST – must have tried fluconazole for treatment of oropharyngeal candidiasis or must be severely immunocompromised and need prophylaxis against invasive Aspergillus or Candida infections - Tolsura - Vfend suspension - ST – must have tried and failed all preferred agents (i.e., each preferred chemical entity) or must provide medical justification as to why each preferred agent is not appropriate for use (e.g., infection being treated is not susceptible to preferred agents); must be 12 years of age and under or unable to swallow capsules/tablets - voriconazole tabs Generic Medically Necessary PA criteria must be met for the following: - voriconazole suspension PA criteria must be met for the following: - Vivjoa	Antimicrobials for Treatment of Vaginal Infections PA Criteria Antimicrobials for Treatment of Vaginal Infections PA form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES - Continued			
Topical Antifungals	<i>All generics unless otherwise specified</i> - ciclopirox (cream & topical soln) - clotrimazole - miconazole - terbinafine 1% cream - tolnaftate 1% cream, powder, spray	- ciclopirox gel, kit, topical shampoo, topical suspension - econazole - Ertaczo - Fungizyl AL - ketoconazole topical foam - miconazole/zinc/pet oint - Mycozyl AL 1% soln - Mycozyl HC gel, liquid - naftifine 1% cream - naftifine 2% cream, gel - Naftin 1% gel - Oxistat - tavaborole soln - Vusion	
Topical Antivirals	acyclovir cream	- acyclovir ointment - penciclovir cream - docosanol OTC cream	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTI-INFECTIVES - Continued			
Vaginal Antimicrobials	<i>Antibacterials – oral</i> - metronidazole <i>Antibacterials – intravaginal</i> - Cleocin 2% cream - metronidazole vaginal gel - Nuessa - Xaciato - ST – previous trial and failure of a preferred intravaginal antibacterial agent <i>Antifungals</i> - clotrimazole OTC - QL – 2 treatment courses/month - miconazole cream OTC - QL – 2 treatment courses/month - tioconazole OTC - QL – 2 treatment courses/month - terconazole cream	<i>Antibacterials – oral</i> - Solosec - tinidazole - ST – must have tried and failed metronidazole or provide medical justification as to why metronidazole is not appropriate for use (e.g., infection being treated is not susceptible to preferred agent) <i>Antibacterials – intravaginal</i> - Cleocin Ovules - Clindesse - Vandazole Generic Medically Necessary PA criteria must be met for the following: - clindamycin 2% cream <i>Antifungals</i> - Gynazole-1 - miconazole combination pack OTC - QL – 2 treatment courses/month - miconazole suppositories OTC - QL – 2 treatment courses/month - miconazole suppositories (Rx) - terconazole suppositories	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTIMIGRAINE			
Antimigraine Preparations	• rizatriptan ○ QL – 1 box – 12 tabs/30 days • rizatriptan ODT ○ QL – 1 box – 12 tabs/30 days • sumatriptan nasal spray ○ QL – 1 box – 6 inhalers/30 days • sumatriptan tablets ○ QL – 1 box – 9 tabs/30 days • sumatriptan stat dose or stat dose refill package ○ QL – 1 box – 2 injections/30 days • sumatriptan vial ○ QL – 2 vials – 2 injections/30 days PSQC/PA criteria must be met for the following: • Nurtec ODT ○ QL – 8 tabs/30 days for acute treatment; ○ QL – 16 tabs/30 days for preventative treatment • Ubrelvy ○ QL – 10 tabs/20 days Prophylaxis PSQC/PA criteria must be met for the following: • Aimovig ○ QL – 140 mg/month • Ajovy ○ QL – 225 mg/month or 675 mg/3 months • Emgality ○ QL migraine – 240 mg loading dose; then 120 mg/month ○ QL cluster headache – 300mg at start of headache and once monthly thereafter until end of headache • Qulipta ○ QL – 1 tab/day	• almotriptan ○ QL – 1 box – 6 tabs/30 days • frovatriptan ○ QL – 1 box – 9 tabs/30 days • naratriptan ○ QL – 1 box – 9 tabs/30 days • Relpax ○ QL – 1 box – 6 tabs/30 days • sumatriptan/naproxen ○ QL – 1 box – 9 tabs/30 days ○ ST – member must have tried and failed one preferred rizatriptan and one preferred sumatriptan product (supported by claims history or chart documentation) AND medical justification for use of naproxen/sumatriptan • Symbravo ○ QL – 1 bottle – 9 tabs/30 days ○ ST – member must have tried and failed naproxen/sumatriptan (supported by claims history or chart documentation) AND medical justification for use of Symbravo • Tosymra soln • Zembrace SymTouch ○ QL – 1 box (4 injections)/30 days • zolmitriptan ○ QL – 1 box – 6 tabs/30 days • zolmitriptan nasal spray ○ QL – 1 box – 6 inhalers/30 days • zolmitriptan ODT ○ QL – 1 box – 6 tabs/30 days PSQC/PA criteria must be met for the following: • Elyxyb ○ QL – 6 bottles/30 days	Antimigraine PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ANTIMIGRAINE - Continued			
Antimigraine Preparations - Continued		PSQC/PA criteria must be met for the following: - Reyvow - QL – 50 mg dose – 4 (50 mg) tabs/30 days - QL – 100 mg dose – 4 (100 mg) tabs/30 days - QL – 200 mg dose – 8 (100 mg) tabs/30 days - Zavzpret - QL – 6 devices/22 days Generic Medically Necessary PA criteria must be met for the following: - eletriptan Prophylaxis PSQC/PA criteria must be met for the following: - Vyepti - QL – 3 mL/90 days	Antimigraine PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CARDIOVASCULAR			
ACE Inhibitors	- benazepril - enalapril - fosinopril - lisinopril - ramipril	- captopril - enalapril 1 mg/mL soln - ST – must be under 12 years of age or unable to swallow tablets - moexipril - perindopril - Qbrelis - ST – must be 6 years of age or older and less than 12 years of age OR 12 years of age and older AND unable to swallow tablets - quinapril - trandolapril	
ACE Inhibitor Combinations	<i>ACE Inhibitors with Calcium Channel Blockers</i> - amlodipine/benazepril - QL – 30 caps/30 days <i>ACE Inhibitors with Diuretics</i> - benazepril/HCTZ - enalapril/HCTZ - lisinopril/HCTZ	<i>ACE Inhibitors with Calcium Channel Blockers</i> - trandolapril/verapamil - QL – 30 caps/30 days <i>ACE Inhibitors with Diuretics</i> - captopril/HCTZ - fosinopril/HCTZ - quinapril/HCTZ - Widaplik - ST – trial and failure of individual components	
Angiotensin Receptor Blockers	- Edarbi; irbesartan; losartan 100 mg; olmesartan 20 mg; olmesartan 40 mg; telmisartan; valsartan 320 mg - QL – 1 tab/day - losartan 25 mg; losartan 50 mg; valsartan 40 mg; valsartan 80 mg; valsartan 160 mg - QL – 2 tabs/day - olmesartan 5 mg - QL – 3 tabs/day	- Arbli suspension; valsartan soln - ST – must be unable to swallow tablets - candesartan 4 mg, 8 mg, 16 mg - QL – 2 tabs/day - candesartan 32 mg - QL – 1 tab/day Generic Medically Necessary PA criteria must be met for the following: - azilsartan - QL – 1 tab/day	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CARDIOVASCULAR - Continued			
Angiotensin Receptor Blocker Combinations	Angiotensin Receptor Blockers with Diuretics • Edarbyclor • losartan/HCTZ • valsartan/HCTZ Angiotensin Receptor Blockers with Calcium Channel Blockers N/A Angiotensin Receptor Blockers with Calcium Channel Blockers and Diuretics N/A	Angiotensin Receptor Blockers with Diuretics • candesartan/HCTZ • irbesartan/HCTZ • olmesartan/HCTZ • telmisartan/HCTZ Angiotensin Receptor Blockers with Calcium Channel Blockers • olmesartan/amlodipine ○ ST – trial and failure of individual components • telmisartan/amlodipine ○ ST – trial and failure of individual components • valsartan/amlodipine ○ ST – trial and failure of individual components Angiotensin Receptor Blockers with Calcium Channel Blockers and Diuretics • amlodipine/olmesartan/HCTZ ○ ST – trial and failure of individual components • amlodipine/valsartan/HCTZ ○ ST – trial and failure of individual components	
Beta Adrenergic Blockers	• acebutolol • atenolol • bisoprolol • carvedilol • labetalol • metoprolol • metoprolol succinate ER • nadolol • nebivolol • propranolol • propranolol ER caps • sotalol	• betaxolol • carvedilol ER cap ○ QL – 1 cap/day • Hemangeol soln ○ ST – must be 5 weeks of age or older and less than or equal to 1 year of age • Kapsargo • Lopressor oral soln ○ ST – must be unable to swallow tablet formulation • pindolol • Sotylize oral soln ○ ST – must be under 12 years of age or unable to swallow capsules/tablets • timolol	
Beta Adrenergic Blockers with Diuretics	• atenolol/chlorthalidone • bisoprolol/HCTZ	• metoprolol/HCTZ	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CARDIOVASCULAR - Continued			
Calcium Channel Blockers	Combinations N/A Dihydropyridine - amlodipine - felodipine ER - nifedipine (short-acting) - nifedipine ER Liquid Formulation - Norliqva - ST – must be unable to swallow tablets Non-Dihydropyridine - diltiazem (long-acting formulations) - diltiazem (non-time released) - nimodipine - verapamil (long-acting formulations) - verapamil (non-time released)	PA criteria must be met for the following: Antiarrhythmic - Cardamyst nasal spray Combinations - amlodipine/atorvastatin - ST – prescriber must provide documentation that separate components are not suitable for use Dihydropyridine - isradipine (non-time released) - nicardipine (non-time released) - nisoldipine Liquid Formulation - Katerzia - ST – must be 6 years of age or older and less than 12 years of age OR 12 years of age and older and unable to swallow tablets AND previous trial and failure of Norliqva OR medical rationale for use - Nymalize - ST – must be 18 years of age or older AND unable to swallow capsule formulation - Sdamlo - ST – must be 6 years of age or older and less than 12 years of age OR 12 years of age and older and unable to swallow tablets AND previous trial and failure of Norliqva OR medical rationale for use Non-Dihydropyridine - Matzim LA - verapamil ER PM - Verelan PM	Cardamyst PA Criteria
Miscellaneous Cardiac Agents	PA criteria must be met for the following: - Corlanor soln - ivabradine - sacubitril/valsartan	PA criteria must be met for the following: - Camzyos - Entresto sprinkle capsules - Myqorzo - Verquvo	Cardiac Agents PA Criteria Cardiac Agents PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS			
Agents for the Treatment of Opioid Use Disorder or Overdose	<i>Agents for Opioid Use Disorder – oral</i> - buprenorphine sublingual tablets - AGE – 16 years of age and older - QL – 24mg/day - buprenorphine/naloxone sublingual tablets - AGE – 16 years of age and older - QL – 24mg/day - Suboxone Film - AGE – 16 years of age and older - QL – 24mg/day - Zubsolv - AGE – 16 years of age and older - QL – 17.2mg/day <i>Agents for Opioid Use Disorder – injectable</i> PA criteria must be met for the following: - Brixadi - Sublocade <i>Agents for Opioid Overdose</i> - Kloxxado - nalmefene - naloxone injection - naloxone nasal spray - Narcan Nasal - Rextovy - Opvee - Zimhi	<i>Agents for Opioid Use Disorder – oral</i> Generic Medically Necessary PA criteria must be met for the following: - buprenorphine/naloxone sublingual films <i>Agents for Opioid Use Disorder – injectable</i> - N/A <i>Agents for Opioid Overdose</i> - Zurnai	Opioid Use Disorder Treatments

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - continued			
Antiemetic/Antivertigo Agents <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	<i>Appetite Stimulant</i> N/A <i>H1 Antagonist/Vitamin</i> - Diclegis - QL – 4 tabs/day; Max 270/365 days <i>Selective 5-HT3 Receptor Antagonist</i> - ondansetron oral tablets - QL – 90 tabs/30 days - ondansetron oral disintegrating tablets (4 mg and 8 mg) - QL – 90 tabs/30 days - ondansetron oral soln - QL – 1 bottle/Rx - ondansetron soln for injection <i>Substance P-Neurokinin 1 Receptor Antagonist</i> - aprepitant 40 mg and 80 mg oral capsules - QL – 6 caps/Rx - aprepitant 80 mg/125 mg tripack - QL – 2 packs (6 caps)/Rx - fosaprepitant vials, Navitrox vials - QL – 2 vials/Rx <i>Substance P-NK 1 Antagonist/Selective 5-HT3 Antagonist</i> N/A	<i>Appetite Stimulant</i> PSQC criteria must be met for the following: - dronabinol <i>H1 Antagonist/Vitamin</i> - Bonjesta - QL – 2 tabs/day; Max 270/365 days Generic Medically Necessary PA criteria must be met for the following: - doxylamine/pyridoxine oral tabs <i>Selective 5-HT3 Receptor Antagonist</i> - Anzemet oral tabs - QL – 10 units/Rx - ST – must have previous trial of ondansetron – any formulation AND provide medical justification for use of the requested agent over ondansetron^ - granisetron oral tablets; granisetron soln for injection - ST – must have previous trial of ondansetron – any formulation AND provide medical justification for use of the requested agent over ondansetron^ - ondansetron 16 mg ODT - QL – 3 tablets/30 days - palonosetron injection - QL – 1 vial/Rx - ST – must have previous trial of ondansetron – any formulation AND provide medical justification for use of the requested agent over ondansetron^	Dronabinol PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - continued			
Antiemetic/Antivertigo Agents - continued		<i>Selective 5-HT3 Receptor Antagonist continued</i> - Posfrea - QL – 1 vial/Rx - ST – must have previous trial of generic palonosetron within the past 90 days AND provide medical justification for use of Posfrea over generic palonosetron injection - Sancuso transdermal system - ST – prescriber has submitted medical justification for use of Sancuso (granisetron) patch over generic granisetron tablet and injectable formulations - Sustol - ST – prescriber has submitted medical justification for use of Sustol (granisetron) injection (prefilled syringe) over generic granisetron tablet and injectable formulations <i>Substance P-Neurokinin 1 Receptor Antagonist</i> - aprepitant 125 mg oral capsules - QL – 6 caps/Rx - Cinvanti injection - QL – 2 vials/Rx - Emend IV soln - QL – 2 vials/Rx - Emend suspension - QL – 3 packets /Rx - ST – must have tried Emend oral capsules or have inability to swallow or tolerate the capsule formulation - Focinvez - QL – 2 vials/Rx <i>Substance P-NK 1 Antagonist/Selective 5-HT3 Antagonist</i> - Akynzeo - ST – must have tried and failed combination therapy with preferred agents of the same classes or provide medical justification for use of the combination product	Dronabinol PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED		NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS – continued				
Antiseizure Agents <i>*For all gabapentin formulations max total daily dose of 3,600 mg /day applies</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	- carbamazepine IR/ER tab, ER cap, chew, susp - Carbatrol - Celontin - clobazam tab - QL for 10 mg tab – 8 tabs/day - QL for 20 mg tab – 4 tabs/day - clobazam susp - QL – 32 mL/day - Depakote Sprinkle - diazepam rectal gel - QL – 10 doses/30 days - Dilantin cap, chew, susp - divalproex DR, ER, sprinkle cap - ethosuximide cap, soln - felbamate susp - Felbatol tablets - fosphenytoin - gabapentin cap, tab, soln* - lacosamide tab - Lamictal IR/XR/ODT Starter Kit - QL – 1 kit/90 days - lamotrigine IR tab, chew, ODT, ER tab - levetiracetam IR, ER, soln, inj - Lyrica soln - QL – 30 mL/day	- Lyrica cap - QL for 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg cap – 3 caps/day - QL for 225 mg or 300 mg cap – 2 caps/day - midazolam syrup - Nayzilam - QL – 10 doses/30 days - Neurontin cap, tab, soln* - oxcarbazepine tab, susp - Oxtellar XR - phenobarbital tab, soln, inj - Phenytek - phenytoin cap, chew, susp, inj - pregabalin cap - QL for 25 mg, 50 mg, 75 mg 100 mg, 150 mg, 200 mg cap – 3 caps/day - QL for 225 mg or 300 mg cap – 2 caps/day - primidone - Relgaabi cap - Roweepra	PA criteria must be met for the following: - Aptiom - Briviact inj, soln, tab - Brivaracetam inj, soln, tab - Diacomit - Elepsia XR - Epidiolex - Fintepla - Fycompa tab, susp - Gabarone* - ST – prescriber has submitted medical justification for use of Gabarone (gabapentin) tablet over preferred gabapentin capsules - lacosamide inj, soln - Libervant - QL – 10 doses/30 days - Motpoly XR - rufinamide tabs/susp - Spritam - Subvenite IR tab - Subvenite oral suspension - ST – must be 2 years of age or older and less than 12 years of age OR 12 years of age or older and unable to swallow tablets - Sympazan - QL for 5 mg and 10 mg films – 8 films/day - QL for 20 mg films – 4 films/day - ST –must have trial and failure of clobazam tablet or suspension AND prescriber has submitted medical justification for the use of Sympazan (clobazam) film over clobazam tablet and suspension^ - vigabatrin - Vigadrone - Vigafyde - Vigpoder	Antiseizure Agents Prior Authorization Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Antiseizure Agents - continued <i>*For all gabapentin formulations max total daily dose of 3,600 mg/day applies</i>	- Tegretol IR tab, XR tab, susp - tiagabine - topiramate tab, sprinkle cap (generic Topamax) - topiramate ER sprinkle cap (generic Qudexy) - QL – 2 caps/day - ST – must be 2 years of age or older and less than 12 years of age OR 12 years of age or older and unable to swallow capsules - Trokendi XR - QL for any strength – 2 caps/day - valproate inj - valproic acid cap, soln - Valtoco - QL – 10 doses/30 days - zonisamide cap PA criteria must be met for the following: - Eprontia - QL – 16 mL/day	- Xcopri tab - Xcopri Titration Pak - QL – 1 Pak/90 days - Zonisade - Ztalmey PA criteria AND Generic Medically Necessary PA criteria must be met for the following: - felbamate - lamotrigine IR/ODT starter kit; Subvenite IR starter kit - levetiracetam ODT - methsuximide - oxcarbazepine ER tab (generic Oxtellar) - perampanel tab - pregabalin soln - rufinamide 200 mg tab - topiramate ER capsule (generic Trokendi XR) - topiramate soln (generic Eprontia)	Antiseizure Agents Prior Authorization Criteria
Gastroprotective Agents	Celebrex	- diclofenac-misoprostol delayed release tablets - ibuprofen-famotidine - naproxen-esomeprazole magnesium - Vyscoxa - ST – must be 2 years of age or older and less than 12 years of age OR 12 years of age or older and unable to swallow capsules Generic Medically Necessary PA criteria must be met for the following: - celecoxib	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Alzheimer's and Dementia Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	- donepezil ODT, tab - ergoloid mesylates - galantamine ER cap, IR tab - galantamine oral soln - ST – must be unable to swallow tablet formulation, as supported by chart documentation - memantine ER cap, IR tab, oral soln, titration pack - rivastigmine cap, patch	- Namzaric - ST – prescriber must provide documentation supporting separate components are not suitable for use; OR history of Namzaric (memantine/ donepezil) capsules for 90 of the past 120 days^ - Zunveyl - ST – trial and failure of galantamine (any formulation) AND prescriber has submitted medical justification for use; OR history of Zunveyl (benzgalantamine) for 90 of the past 120 days^ Generic Medically Necessary PA criteria must be met for the following: - memantine/donepezil (generic Namzaric)	Mental Health Medications Medical Necessity Prior Authorization Form Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Anti-Anxiety and Related Disorders <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	<i>Benzodiazepines</i> PA criteria must be met for the following: - alprazolam IR/XR tab, ODT, oral conc soln - chlordiazepoxide - chlordiazepoxide/amitriptyline - clonazepam tab, ODT - clorazepate dipotassium - diazepam oral soln, oral conc soln, tab - lorazepam inj soln, oral conc soln, tab - oxazepam <i>Non-Benzodiazepines</i> - buspirone tab - cycloheptadine syrup, tab - hydroxyzine hcl syrup, tab - hydroxyzine pamoate - prazosin	<i>Benzodiazepines</i> PA criteria must be met for the following: - Loreev XR <i>Non-Benzodiazepines</i> - Bucapsol - ST – must have previous trial and failure of buspirone tablet AND prescriber must provide rationale for Bucapsol over buspirone tablet^ - meprobamate - ST – must have previous trial and failure of buspirone IR tablet and hydroxyzine AND prescriber must provide rationale for meprobamate use over buspirone IR tablet and hydroxyzine; OR history of meprobamate for 90 of the past 120 days^ PA criteria must be met for the following: - Igalmi	Benzodiazepine and Opioid Concurrent Therapy PA Form Igalmi Mental Health Medications Medical Necessity Prior Authorization Form Sedative Hypnotics- Benzodiazepine PA with QL Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED		NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued				
Mental Health Agents: Antidepressant Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	MAO-I N/A Miscellaneous Agents - Auvelity - bupropion IR/ER/SR/XL tab - mirtazapine ODT, tab - nefazodone - trazodone tab PA criteria must be met for the following: - Zurzuvae SNRI PA criteria must be met for the following*: - desvenlafaxine ER - desvenlafaxine succinate ER - duloxetine - Fetzima cap/titration pack - Savella tab/titration pack - venlafaxine besylate ER tab - venlafaxine hcl IR/ER tab, ER cap	SSRI PA criteria must be met for the following*: - citalopram tab - citalopram oral soln; escitalopram oral soln; fluoxetine oral soln - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule/tablet formulation, as supported by chart documentation; OR history of respective oral solution for 90 of the past 120 days^ - escitalopram tab - fluoxetine IR/DR cap, tab - fluvoxamine tab - paroxetine IR/ER tab	MAO-I - Emsam; Marplan; phenelzine; tranylcypromine - ST – must have previous trial and failure of one SSRI and one SNRI agent for at least 4 weeks each AND prescriber has submitted medical justification for use; OR history of requested agent for 90 of the past 120 days^ Miscellaneous Agents - bupropion ER (generic Forfivo XL) 450 mg tablet - ST – prescriber has submitted medical justification for use of bupropion ER 450 mg tablet over preferred bupropion agents; OR history of bupropion ER 450 mg tablet for 90 of the past 120 days^ - Exxua tab, titration pack - ST – must have trial and failure of two preferred antidepressant agents for at least 4 weeks each; OR history of requested agent for 90 of the past 120 days^ - Raldesy - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow tablet formulation, as supported by chart documentation; OR history of Raldesy oral solution for 90 of the past 120 days^ PA criteria must be met for the following: - Spravato SNRI PA criteria must be met for the following*: - Drizalma sprinkle - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule formulation, as supported by chart documentation; OR history of Drizalma sprinkle capsules for 90 of the past 120 days^ PA criteria AND Generic Medically Necessary PA criteria must be met for the following: - milnacipran tab/titration pack	Mental Health Medications Medical Necessity Prior Authorization Form Spravato PA *PA is required for duplication of SSRI/SNRI/NRI therapy SSRI/SNRI/NRI Duplicate Therapy PA with QL Utilization Edits for Mental Health Medications Zurzuvae

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Antidepressant Agents – continued <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	SSRI-continued - paroxetine oral soln - ST – must be unable to swallow tablet formulation, as supported by chart documentation; OR history of paroxetine oral suspension for 90 of the past 120 days^ - sertraline tab - sertraline conc soln - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow tablet formulation, as supported by chart documentation; OR history of sertraline oral concentrate for 90 of the past 120 days^ - Trintellix - vilazodone TCA - amitriptyline - amoxapine - clomipramine - desipramine - doxepin cap, oral soln - imipramine hcl - imipramine pamoate - nortriptyline cap - nortriptyline oral soln - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule formulation, as supported by chart documentation; OR history of nortriptyline oral solution for 90 of the past 120 days^ - protriptyline	SSRI PA criteria must be met for the following*: - citalopram cap - ST – must have previous trial and failure of citalopram tablet AND prescriber has submitted medical justification for the use of citalopram capsule over citalopram tablet; OR history of citalopram capsule for 90 of the past 120 days^ - escitalopram cap - ST – must have previous trial and failure of escitalopram tablet AND prescriber has submitted medical justification for the use of escitalopram capsule over escitalopram tablet; OR history of escitalopram capsule for 90 of the past 120 days^ - fluvoxamine CR cap - ST – must have previous trial and failure of fluvoxamine IR tablet formulation AND prescriber has submitted medical justification for the use of fluvoxamine ER capsule over fluvoxamine IR tablet; OR history of fluvoxamine ER capsule for 90 of the past 120 days^ - sertraline cap - ST – must have trial and failure of sertraline tablet AND prescriber has submitted medical justification for the use of sertraline capsule over sertraline tablet; OR history of sertraline capsule for 90 of the past 120 days^ TCA - trimipramine maleate - ST – must have trial and failure of all preferred tricyclic antidepressants OR medical justification for the use of trimipramine over all preferred tricyclic antidepressants^	Mental Health Medications Medical Necessity Prior Authorization Form Spravato PA *PA is required for duplication of SSRI/SNRI/NRI therapy SSRI/SNRI/NRI Duplicate Therapy PA with QL Utilization Edits for Mental Health Medications Zuruvae

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED		NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued				
Mental Health Agents: Antipsychotic and Antimanic Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	Antipsychotics – First Generation PA criteria must be met for the following: • chlorpromazine inj soln, oral conc, tab • fluphenazine decanoate • fluphenazine hcl elixir, inj soln, oral conc soln, tab • haloperidol decanoate IM soln • haloperidol lactate oral conc, inj soln • haloperidol tab • loxapine • molindone • perphenazine • perphenazine/amitripty line • prochlorperazine edisylate inj soln • prochlorperazine maleate tab • thioridazine • thiothixene • trifluoperazine Antipsychotics – Miscellaneous N/A	Antipsychotics – Second Generation PA criteria must be met for the following: • Abilify Asimtufii • Abilify Maintena (syringe/vial) • aripiprazole tabs • aripiprazole ODT, soln ○ ST – must be under 12 years of age OR 12 years of age or older and unable to swallow tablet formulation (as supported by chart documentation); OR history of requested agent for 90 of the past 120 days^ • Aristada/Aristada Initio • asenapine SL • Caplyta • clozapine tab • clozapine ODT ○ ST – must have trial and failure of clozapine tablet AND prescriber has submitted medical justification for the use of clozapine ODT over clozapine tablet; OR history of clozapine ODT for 90 of the past 120 days^	Antipsychotics – First Generation PA criteria must be met for the following: • pimozide ○ ST – member has tried and failed two of the following for 4 weeks each: aripiprazole, haloperidol, risperidone; OR history of pimozide for 90 of the past 120 days^ Antipsychotics – Second Generation PA criteria must be met for the following: • Bysanti tab, titration pack ○ ST – must have trial and failure of Fanapt OR medical justification for the use of Bysanti over Fanapt; OR history of the requested agent for 90 of the past 120 days^ • Fanapt tab, titration pack ○ ST – must have trial and failure of one preferred antipsychotic agent OR medical justification for the use of Fanapt over all preferred agents; OR history of the requested agent for 90 of the past 120 days^ • Nuplazid cap, tab • Opipza ○ ST – must have trial and failure of aripiprazole tablet AND prescriber has submitted medical justification for the use of Opipza over aripiprazole tablet; OR history of Opipza for 90 of the past 120 days^ • Secuado ○ ST – must have trial and failure of asenapine SL AND prescriber has submitted medical justification for the use of Secuado patch over asenapine SL; OR history of Secuado patch for 90 of the past 120 days^ • Versacloz ○ ST – must be unable to swallow tablet formulation, as supported by chart documentation	Antipsychotic Therapy PA with QL Mental Health Medications Medical Necessity Prior Authorization Form Nuplazid PA Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED		NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued				
Mental Health Agents: Antipsychotic and Antimanic Agents – continued <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	Antimanic Agents • Equetro • lithium cap, IR/ER tab • lithium oral soln ○ ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule/tablet formulation, as supported by chart documentation	Antipsychotics – Second Generation – continued • Erzofri • Invega Hafyera • Invega Sustenna • Invega Trinza • lurasidone • Lybalvi • olanzapine IM soln, ODT, tab • olanzapine/fluoxetine • paliperidone tab • quetiapine IR/ER tab • Rexulti • Risperdal Consta • risperidone tab • risperidone ODT, soln ○ ST – must be under 12 years of age OR unable to swallow tablet formulation (as supported by chart documentation); OR history of requested agent for 90 of the past 120 days^ • Uzedy • Vraylar • ziprasidone cap, IM soln • Zyprexa Relprevv	Antipsychotics – Second Generation – continued PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • risperidone microspheres inj soln Antipsychotics – Miscellaneous PA criteria must be met for the following: • Cobenfy tab, titration pack Antimanic Agents N/A	Antipsychotic Therapy PA with QL Mental Health Medications Medical Necessity Prior Authorization Form Nuplazid PA Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Insomnia Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	<i>Benzodiazepines</i> PA criteria must be met for the following: - estazolam - temazepam - triazolam <i>Hypnotic/Sedative</i> PA criteria must be met for the following: - Belsomra - eszopiclone - ramelteon - zaleplon - zolpidem IR/CR tab <i>Miscellaneous</i> - doxepin (generic Silenor)	<i>Benzodiazepines</i> PA criteria must be met for the following: - flurazepam - ST – must have trial and failure of all preferred benzodiazepine agents for insomnia OR medical justification for use over preferred benzodiazepine agents for insomnia^ - quazepam - ST – must have trial and failure of all preferred benzodiazepine agents for insomnia OR medical justification for use over preferred benzodiazepine agents for insomnia^ <i>Hypnotic/Sedative</i> PA criteria must be met for the following: - Dayvigo; Quviviq - ST – must have trial and failure of Belsomra OR prescriber has submitted medical justification for the use of requested agent over Belsomra^ - Edluar SL 5 mg, 10 mg - ST – must have trial and failure of zolpidem tablet AND prescriber has submitted medical justification for the use of Edluar SL over zolpidem tablet^ - Hetlioz LQ oral susp - tasimelteon cap - zolpidem 7.5 mg cap - ST – must have trial and failure of zolpidem IR 5 mg^ - zolpidem SL 1.75 mg and 3.5 mg - ST – prescriber has submitted medical justification for the use of zolpidem sublingual tablets AND member is not using concomitantly with other zolpidem strengths/formulations <i>Miscellaneous</i> - N/A	Benzodiazepine and Opioid Concurrent Therapy PA Form Hetlioz/Hetlioz LQ PA Hetlioz/Hetlioz LQ PA Form Mental Health Medications Medical Necessity Prior Authorization Form Sedative Hypnotics- Benzodiazepine PA with QL Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Narcolepsy and Cataplexy Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i>	PA criteria must be met for the following: • armodafinil • modafinil • Xyrem	PA criteria must be met for the following: • Sunosi • Wakix • Xywav PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • sodium oxybate	Narcolepsy Agents PA Narcolepsy Agents PA Form Mental Health Medications Medical Necessity Prior Authorization Form Utilization Edits for Mental Health Medications
Mental Health Agents: Non-Stimulant ADHD Agents <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	PA criteria must be met for the following: • clonidine IR/ER tab, patch • guanfacine IR/ER tab • Onyda XR oral susp PA criteria must be met for the following *: • atomoxetine • Qelbree ○ ST – previous trial and failure of a preferred ADHD agent (stimulant or non-stimulant); OR history of Qelbree (viloxazine) for 90 of the past 120 days^	PA criteria must be met for the following *: • Atency; atomoxetine solution ○ ST – must be 6 years of age or older and less than 12 years of age OR 12 years of age or older and unable to swallow capsule formulation (as supported by chart documentation)	Clonidine and Guanfacine PA Mental Health Medications Medical Necessity Prior Authorization Form *PA is required for duplication of SSRI/SNRI/NRI therapy SSRI/SNRI/NRI Duplicate Therapy PA with QL Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Mental Health Agents: Stimulants <i>Please refer to Mental Health Medications and Utilization Edits list for drug-specific age and quantity limits. If request is not meeting permitted limit(s), a PA submission will be required.</i> <i>^Note: to meet step therapy requiring historical use of another agent, history must be supported by claims history or chart documentation</i>	PA criteria must be met for the following: - amphetamine - amphetamine/dextroamphetamine ER cap, IR tab - Azstarys - dextroamphetamine IR tab, ER cap - dextroamphetamine oral soln - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule/tablet formulation, as supported by chart documentation - dexmethylphenidate IR tab, XR cap - Dyanavel XR oral susp, XR tab - Jornay PM - ST – must have trial and failure of at least one preferred long-acting methylphenidate product OR medical justification for use of Jornay PM; OR history of the requested agent for 90 of the past 120 days^ - methamphetamine - methylphenidate chew, ER (CD) cap, ER cap, IR/ER tab, oral soln, patch - Quillivant XR - Quillichew ER - Vyvanse cap - Vyvanse chew - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule formulation, as supported by chart documentation	PA criteria must be met for the following: - Adzenys XR ODT - ST – must have trial and failure of Dyanavel XR (amphetamine) chew or suspension OR medical justification for the use of Adzenys XR (amphetamine) over Dyanavel XR (amphetamine); OR history of the requested agent for 90 of the past 120 days^ - amphetamine/dextroamphetamine ER capsule (generic Mydayis) - ST – must have trial and failure of amphetamine/dextroamphetamine ER capsules (generic Adderall XR) or medical justification for use of generic Mydayis over generic Adderall XR; OR history of the requested agent for 90 of the past 120 days^ - Arynta - ST – must provide medical justification for use over Vyvanse chewable tablets - Cotempla XR ODT; Relexxi; Zenzedi - ST – must have trial and failure of two preferred stimulants (different chemical entities) OR medical justification for the use of the non-preferred agent over all preferred agents; OR history of the requested agent for 90 of the past 120 days^ - methylphenidate ER capsule (generic Aptensio XR) - ST – must have trial and failure of at least one preferred long-acting methylphenidate product OR medical justification for use of methylphenidate ER capsule (generic Aptensio XR); OR history of the requested agent for 90 of the past 120 days^ - Procentra - ST – must be under 12 years of age OR 12 years of age or older and unable to swallow capsule/tablet formulation, as supported by chart documentation AND prescriber has submitted medical justification for use of Procentra over dextroamphetamine oral solution - Xelstrym - ST – must provide medical justification for topical formulation PA criteria AND Generic Medically Necessary PA criteria must be met for the following: - amphetamine XR ODT - lisdexamfetamine capsule - lisdexamfetamine chewable - methylphenidate ER ODT	Mental Health Medications Medical Necessity Prior Authorization Form Stimulants Therapy PA with QL Utilization Edits for Mental Health Medications

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Movement Disorder Agents	• benztropine tablet, injection • trihexyphenidyl tablet, soln PA criteria must be met for the following: • Austedo • Austedo XR • Austedo XR Titration Kit • Ingrezza • Ingrezza sprinkle capsules • Ingrezza Therapy Pack • tetrabenazine	N/A	Movement Disorder Agents PA Criteria
Narcotic Antitussives and Combinations <i>See Opioid Overutilization with Age and Quantity Limits PA Criteria for product-specific age and quantity limits</i> <i>*Note: All narcotic antitussives will require PA for members under 18 years of age *</i>	PSQC criteria must be met for the following: • guaifenesin/codeine 100-10mg/5mL soln • hydrocodone/ homatropine syrup • hydrocodone/homatropine tab • Hydromet syrup • promethazine VC/codeine syrup • promethazine with codeine	PSQC criteria must be met for the following: • hydrocodone polst/chlorpheniramine polst ER • Tuxarin ER	Opioid Overutilization with Age and Quantity Limits PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Narcotics See Opioid Overutilization with Age and Quantity Limits PA Criteria for product-specific age and quantity limits Note: All codeine products will require PA for members under 18 years of age	Short Acting PSQC/PA criteria must be met for the following: • apap/codeine • buprenorphine inj • butorphanol injection ◦ AGE – 18 years of age and older • butorphanol 10 mg/mL nasal spray • codeine sulfate • codeine/butalbital/apap/caffeine • codeine/butalbital/asa/caffeine • hydrocodone/apap (all formulations/strengths except those listed under non-preferred) • hydrocodone/ibu • hydromorphone • levorphanol • meperidine • morphine • nalbuphine • opium tincture • oxycodone • oxycodone/apap • pentazocine/naloxone • tramadol • tramadol/APAP • Xyvona Long Acting PSQC criteria must be met for the following: • Butrans • fentanyl patches • morphine ER tab (MS Contin)	Short Acting PSQC/PA criteria must be met for the following: • Apadaz • benzhydrocodone/APAP • belladonna and opium suppositories • hydrocodone/apap 10-300 mg/15 mL soln • Nalocet • oxycodone AD • oxymorphone IR • Prolate • Qdolo • RoxyBond • tapentadol IR • tramadol 5 mg/mL soln • Trezix Long Acting PSQC criteria must be met for the following: • Belbuca • hydrocodone ER cap (Zohydro) • Hysingla ER • hydromorphone ER tab (Exalgo) • methadone • morphine ER cap (Avinza, Kadian) • oxycodone ER tab • Oxycontin • oxymorphone ER tab (Opana) • tapentadol ER • tramadol ER (Conzip, Ryzolt, Ultram ER) PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • buprenorphine patches • hydrocodone ER tab (Hysingla ER)	APAP High Dose PA Criteria Benzodiazepine and Opioid Concurrent Therapy PA Form Opioid Overutilization with Age and Quantity Limits PA Criteria Opioid PA Form – Request to Exceed MME Limit Opioid with Concurrent Buprenorphine/Naloxone PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Skeletal Muscle Relaxants	• baclofen • chlorzoxazone • cyclobenzaprine IR (tabs) • methocarbamol • orphenadrine citrate • tizanidine tablets Granules/Liquid Formulation • baclofen 5 mg/5 mL soln; baclofen 10 mg/5 mL soln; baclofen 25 mg/5mL susp; Lyvispah granules ○ ST – must be unable to swallow tablets	• Amrix ○ ST – must try cyclobenzaprine tablets within the past 30 days • dantrolene • Fexmid • metaxalone • Norgesic • Norgesic Forte • Orphengesic Forte • orphenadrine/aspirin/caffeine • Tanlor • tizanidine capsules • Tonmya ○ QL – 2 SL tabs/day ○ ST – must trial cyclobenzaprine IR (tabs) within the past 30 days PA criteria must be met for the following: • carisoprodol ○ QL – 4 tabs/day Generic Medically Necessary PA criteria must be met for the following: • cyclobenzaprine ER (caps) Granules/Liquid Formulation • Ontralfy ○ ST – must be unable to swallow tablets	Carisoprodol Agents PA Criteria Carisoprodol Agents PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
CNS AND OTHERS - Continued			
Smoking Deterrent Agents	Nicotine Replacement • nicotine gum ○ AGE – 10 years of age or older ○ QL – 24 pieces/day • nicotine lozenge ○ AGE – 10 years of age or older ○ QL – 20 pieces/day • nicotine patch ○ AGE – 10 years of age or older ○ QL – 1 patch/day • nicotine patch kit ○ AGE – 10 years of age or older ○ QL – 1 kit/90 days Other Smoking Deterrents • bupropion SR 150 • varenicline ○ AGE – 18 years of age or older ○ QL – 1 starter pack/90 days	Nicotine Replacement • Nicotrol NS ○ AGE – 10 years of age or older ○ QL – 12 bottles/30 days • Nicotrol Inhaler ○ AGE – 10 years of age or older ○ QL – 3 inhalers/31 days Other Smoking Deterrents N/A	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
DERMATOLOGIC			
Acne Agents Note: All Rx acne agents for members over the age of 25 years require step therapy with one covered OTC acne product Note: A 14-day trial each of at least 2 preferred agents is required prior to receiving a non-preferred agent.	All legend generic products are preferred unless otherwise specified - adapalene 0.1% gel (OTC) - AGE – 12 years and older - benzoyl peroxide OTC gel, wash - benzoyl peroxide-erythromycin 5-3% gel - clindamycin 1% gel, lotion, solution, swabs - clindamycin-benzoyl peroxide 1-5% gel - clindamycin-benzoyl peroxide 1.2-5% gel - clindamycin-tretinoin 1.2-0.025% gel - Differin 0.1% cream - AGE – 25 years and under – ST – must have tried a preferred topical tretinoin product - AGE – >25 years – ST – must have tried one covered OTC acne product AND a preferred topical tretinoin product - Differin 0.3% gel - AGE – 25 years and under – ST – must have tried a preferred topical tretinoin product - AGE – >25 years – ST – must have tried one covered OTC acne product AND a preferred topical tretinoin product - Differin gel cleanser - erythromycin 2% gel, solution - Neuac 1.2-5% gel - tretinoin cream - tretinoin gel 0.01%, 0.025% Oral Formulations - Amnesteem - Claravis - Zenatane	All legend brand products are non-preferred unless otherwise specified - adapalene/benzoyl peroxide 0.1-2.5% gel - adapalene/benzoyl peroxide 0.3-2.5% gel - Aklief 0.005% cream - BP 10-1 emulsion - Clindacin 1% foam, kit, kit ETZ, swab - clindamycin 1% foam - clindamycin/benzoyl peroxide 1.2-2.5% gel - clindamycin/benzoyl peroxide 1.2-3.75% gel - dapsone gel - Ery-Pad 2% - Fabior 0.1% foam - Plexion cleanser - SSS 10-5% cream, 10-5% foam - sulfacetamide sod/sulfur 8-4% susp, 9-4% wash, 9-4.25% susp, 9-4.5% wash, 9.8-4.8% wash, 10-2% cream, 10-5% cream, 10-1% emulsion, 10-2% wash, 10-5% wash - sulfacetamide sod 10% topical lotion - Sumadan Kit - Sumaxin 10-4% pads, CP kit - tazarotene 0.1% foam - tretinoin gel 0.05% - tretinoin 0.08% microsphere - Twynéo - ST – trial and failure of concomitant use of individual components for at least 30 days AND rationale for use over separate individual components - Winlevi 1% cream Generic Medically Necessary PA criteria must be met for the following: - adapalene 0.1% cream - adapalene 0.3% gel Oral Formulations - Absorica LD - isotretinoin	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
DERMATOLOGIC - Continued			
Antipsoriatics	• calcipotriene cream • calcipotriene topical soln • Enstilar • Pellix topical soln • Taclonex scalp suspension • tazarotene 0.1% cream • Vectical ointment PA criteria must be met for the following: • acitretin	• calcipotriene 0.005% foam • calcipotriene ointment • calcipotriene/betamethasone ointment • methoxsalen • Sorilux foam • tazarotene 0.05% cream, gel • tazarotene 0.1% gel • Trilitas 0.1% gel Generic Medically Necessary PA criteria must be met for the following: • calcipotriene/betamethasone suspension • calcitriol ointment	Soriatane PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ELECTROLYTE DEPLETERS			
Electrolyte Depleters	Miscellaneous Agents N/A Phosphate Binders - calcium acetate capsules - calcium acetate tabs - calcium carbonate 500 mg - calcium carbonate 500 mg, 750 mg, 1000 mg chew - calcium carbonate 1.25 gm (500 mg elemental calcium) chew - calcium carbonate 1.25 gm (500 mg elemental calcium) tab - calcium carbonate 1250 mg/5 mL susp - QL – 30 mL/day - Magnebind 300 mg tab - QL – 2 bottles (300 tabs)/30 days - sevelamer carbonate powder - sevelamer carbonate tabs Potassium Binders - Lokelma - sodium polystyrene sulfonate powder - SPS (sodium polystyrene sulfonate) suspension - Veltassa	Miscellaneous Agents - Xphozah - ST – must have tried and failed preferred phosphate binders OR submit medical rationale for use over ALL preferred phosphate binders Phosphate Binders - Auryxia - Fosrenol powder packet - ST – member must be under 18 years of age or unable to swallow tablets - lanthanum carbonate chew - sevelamer HCl tabs - Velphoro Generic Medically Necessary PA criteria must be met for the following: - ferric citrate (authorized generic Auryxia) Potassium Binders - Kionex suspension	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE			
Anaphylaxis Agents	epinephrine auto-injector	- Auvi-Q - Epipen - Neffy	
Bone Formation Stimulating Agents	PA criteria must be met for the following: Forteo	PA criteria must be met for the following: - Bonsity - Evenity - teriparatide (authorized generic Bonsity) - Tymlos PA criteria AND Generic Medically Necessary PA criteria must be met for the following: - teriparatide (authorized generic and generic Forteo)	Bone Formation Stimulating Agents PA Criteria Bone Formation Stimulating Agents PA Form
Bone Resorption Inhibitors	<i>Bisphosphonates</i> - alendronate - ibandronate - risedronate tablets - ST – must try alendronate within the past 90 days <i>Bone Modifying Monoclonal Antibodies</i> N/A <i>Calcitonin</i> - calcitonin-salmon nasal <i>SERMs</i> - raloxifene	<i>Bisphosphonates</i> - alendronate oral soln 70mg/75mL - ST – must be 5 years of age or older and less than 12 years of age OR unable to swallow tablets - Fosamax Plus D - ibandronate pre-filled syringe - QL – one single-use, pre-filled syringe per 90 days - risedronate DR (generic Atelvia) <i>Calcitonin</i> - calcitonin (salmon) injection - ST – trial and failure of calcitonin-salmon nasal or medical justification for use over the preferred calcitonin agent <i>Bone Modifying Monoclonal Antibodies</i> PA criteria must be met for the following: - Aukelso - Bildyos - Bilprevda - Bomyntra - Bosaya - Conexence - Enoby - Jubbonti - Jubereq - Osenvelt - Osvyrti - Prolia - Stoboclo - Wyost - Xgeva - Xtrenbo <i>SERMs</i> N/A	Bone Resorption Inhibitors PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
DPP4 Inhibitors and Combination Agents Note: For all DPP-4 Inhibitor and Combination Agents, the following ST applies – member must not be on concomitant GLP-1 receptor agonist and/or combination therapy (i.e., history of use of GLP-1 RA and/or combination therapy within the past 45 days)	DPP4-I - Januvia - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use - Tradjenta - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use DPP4-I & metformin combination - Janumet - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use - Jentadueto - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use - Jentadueto XR - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use - saxagliptin free base/metformin ER (authorized generic Zituvimet XR) - ST – must have tried metformin for 90 of the past 120 days or provide medical justification for use	DPP4-I - alogliptin - ST – must have tried a preferred agent for 90 of the past 120 days or provide medical justification for use - Brynovin oral soln - ST – must be 18 years of age or older and unable to swallow (supported by chart documentation) - saxagliptin - ST – must have tried a preferred agent for 90 of the past 120 days or provide medical justification for use - Zituvio - ST – must have tried a preferred agent for 90 of the past 120 days or provide medical justification for use Generic Medically Necessary PA criteria must be met for the following: - sitagliptin (authorized generic Zituvio) - sitagliptin (generic Januvia) DPP4-I & metformin combination - alogliptin/metformin - ST – must have tried a preferred combination agent for 90 of the past 120 days or provide medical justification for use - Janumet XR; sitagliptin/metformin ER - ST – must have tried a preferred combination agent for 90 of the past 120 days or provide medical justification for use - saxagliptin/metformin ER - ST – must have tried a preferred combination agent for 90 of the past 120 days or provide medical justification for use - Zituvimet - ST – must have tried a preferred combination agent for 90 of the past 120 days or provide medical justification for use	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
DPP4 Inhibitors and Combination Agents - continued <i>Note: For all DPP-4 Inhibitor and Combination Agents, the following ST applies – member must not be on concomitant GLP-1 receptor agonist and/or combination therapy (i.e., history of use of GLP-1 RA and/or combination therapy within the past 45 days)</i>	DPP4-I & thiazolidinedione combination N/A	DPP4-I & metformin combination - continued Generic Medically Necessary PA criteria must be met for the following: • sitagliptin free base/metformin (authorized generic Zituvimet) • sitagliptin free base/metformin (generic Janumet) DPP4-I & thiazolidinedione combination • alogliptin/pioglitazone ○ ST – must have tried and failed combination therapy with preferred agents of the same classes for 90 of the past 120 days or provide medical justification for use	
GLP-1 Receptor Agonists and Combinations	GLP-1 RA PA criteria must be met for the following: • liraglutide (authorized generic and generic Victoza) • Ozempic • Trulicity • Victoza GIP/GLP-1 RA PA criteria must be met for the following: • Zepbound Combination Agents PA criteria must be met for the following: • Soliqua	GLP-1 RA PA criteria must be met for the following: • exenatide • Rybelsus • Wegovy GIP/GLP-1 RA PA criteria must be met for the following: • Mounjaro Combination Agents PA criteria must be met for the following: • Xultophy	GLP-1 RA/GIP RA/Combinations PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
Glucagon Agents	- Baqsimi nasal spray - Gvoke injection - Zegalogue injection	Glucagon Kit	
Growth Hormones	<i>Somatropin products</i> PA criteria must be met for the following: - Genotropin - Norditropin - Serostim <i>Long-acting products</i> PA criteria must be met for the following: - Skytrofa <i>Miscellaneous growth hormone products</i> N/A	<i>Somatropin products</i> PA criteria must be met for the following: - Humatrope - Nutropin AQ - Omnitrope - Zomacton <i>Long-acting products</i> PA criteria must be met for the following: - Ngenla - Sogroya <i>Miscellaneous growth hormone products</i> PA criteria must be met for the following: - Increlex - Voxzogo - Yuviwel	Growth Hormone PA Criteria Growth Hormone for Adults PA Form Growth Hormone for Children PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
Insulins – Intermediate Acting	- Humalog Mix 50/50 - Humulin N (vials) - Humulin N KwikPen - Humulin 50/50 - Humulin 70/30 (all formulations) - insulin aspart 70/30 (Novolog mix ABA – FlexPen and vial) - insulin lispro protamine/insulin lispro KwikPen - Novolog Mix 70/30 (FlexPen and vial) - Novolin N - Novolin N ReliOn (vials only) - Novolin 70/30 - Novolin 70/30 ReliOn (vials only)	- Humalog Mix 75/25 - Novolin N ReliOn (prefilled pen, innolets, syringes and cartridges) - Novolin 70/30 ReliOn (prefilled pen, innolets, syringes and cartridges) - Novolog Mix 70/30 ReliOn (all formulations)	
Insulins – Rapid Acting	- Fiasp (all formulations) - Humalog (cartridge) - Humalog (vial) - Humalog KwikPen 200 units/mL - ST – member requires ≥ 100 units/day of insulin and prescriber is an endocrinologist OR member requires ≥ 100 units/day of insulin and member is not using concomitantly with any insulin delivery device OR prescriber has submitted medical justification for use - insulin aspart (all formulations) - insulin lispro KwikPen and Jr. KwikPen - Novolog (all formulations)	- Admelog - Admelog Solostar - Apidra - Apidra SoloStar - Humalog KwikPen 100 units/mL and Jr. KwikPen - Humalog Tempo Pen - insulin lispro (vial) - Kirsty - Lyumjev - Lyumjev Tempo Pen - Merilog (pen and vial) - Novolog ReliOn (all formulations)	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
Insulins – Short Acting	- Humulin R (all formulations) - Novolin R (all formulations) - Novolin R ReliOn (vials only)	- Afrezza - Novolin R ReliOn (prefilled pen, innolets, syringes and cartridges)	
Insulins – Long Acting	- Langlara - Lantus (cartridges, pens, & vials) - Tresiba FlexTouch and vials	- Basaglar - Basaglar Tempo Pen - insulin degludec FlexTouch & vials - insulin glargine - insulin glargine-yfgn - Levemir (Flextouch, & vials) - Rezvoglar - Semglee - Toujeo Solostar	
Miscellaneous Oral Antidiabetic Agents	<i>Alpha glucosidase inhibitors</i> - acarbose <i>Biguanides</i> - metformin - metformin ER - metformin ER modified release <i>Meglitinide</i> - repaglinide <i>Sulfonylureas and Combinations</i> - glimepiride - glipizide - glipizide ER - glipizide/metformin - glyburide - glyburide/metformin <i>Thiazolidinediones and Combinations</i> - pioglitazone - QL – 1 tablet/day	<i>Alpha glucosidase inhibitors</i> - miglitol <i>Biguanides</i> - metformin ER osmotic - metformin HCl soln - ST – must be 10 years of age or older and less than 12 years of age OR unable to swallow tablets <i>Meglitinide</i> - nateglinide <i>Sulfonylureas and Combinations</i> N/A <i>Thiazolidinediones and Combinations</i> - pioglitazone/glimepiride - ST – prescriber must provide documentation that separate components are unsuitable for use - pioglitazone/metformin - ST – prescriber must provide documentation that separate components are unsuitable for use	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
SGLT Inhibitors and Combinations <i>Note*: For all DPP-4 inhibitor containing agents, the following ST applies – member must not be on concomitant GLP-1 receptor agonist and/or combination therapy (i.e., history of use of GLP-1 RA and/or combination therapy within the past 45 days)</i>	SGLT1-I/SGLT2-I N/A SGLT2-I - Farxiga - Jardiance SGLT2-I & metformin combination - Synjardy - Xigduo XR SGLT2-I & DPP4-I combination* - Glyxambi SGLT2-I, DPP4-I, & metformin combination* N/A	SGLT1-I/SGLT2-I - Inpefa - ST – must try and fail each of the following active ingredients as monotherapy or combination product: canagliflozin, dapagliflozin, empagliflozin OR medical justification for use SGLT2-I - Invokana - Steglatro Generic Medically Necessary PA criteria must be met for the following: - dapagliflozin (Farxiga ABA) SGLT2-I & metformin combination - Invokamet - Invokamet XR - Segluromet - Synjardy XR Generic Medically Necessary PA criteria must be met for the following: - dapagliflozin/metformin (Xigduo XR ABA) SGLT2-I & DPP4-I combination* - Steglujan - ST – must have tried and failed Glyxambi or combination therapy with preferred agents of the same classes OR prescriber has submitted medical justification for use over preferred agents SGLT2-I, DPP4-I, & metformin combination* - Trijardy XR - ST – must have tried and failed combination therapy with preferred agents of the same classes or provide medical justification for use over preferred agents	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ENDOCRINE - Continued			
Testosterones <i>See Testosterone PA Criteria for product-specific age and quantity limits</i>	Injectable Agents PA criteria must be met for the following: • Depo-Testosterone • testosterone cypionate Oral Agents N/A Topical Agents PA criteria must be met for the following: • Testim 1% (50 mg)/5 gm gel tubes • testosterone 1% (25 mg)/2.5 gm gel packets • testosterone 1% (50 mg)/5 gm gel packets • testosterone 1% (12.5 mg)/act gel pump • testosterone 1.62% (20.25 mg)/act metered pump gel	Injectable Agents PA criteria must be met for the following: • Aveed • Azmiro • Testopel pellet • testosterone enanthate • Xyosted Oral Agents PA criteria must be met for the following: • Danazol • Jatenzo • Methitest • methyltestosterone • Tlando Topical Agents PA criteria must be met for the following: • Natesto • testosterone 1% (50 mg)/5 gm gel tubes • testosterone 1.62% (40.5 mg)/2.5 gm gel packets • testosterone 1.62% (20.25 mg)/1.25 gm gel packets • testosterone 2% (10 mg)/act metered pump • testosterone 30 mg/act soln • Vogelxo 1% (50 mg)/5 gm gel packets • Vogelxo 1% (12.5 mg)/act gel pump	Testosterones PA Criteria Testosterones PA Form
Urea Cycle Disorders (Hyperammonemia Treatments)	PA criteria must be met for the following: • Carbaglu • Pheburane • sodium phenylbutyrate powder • sodium phenylbutyrate tab	PA criteria must be met for the following: • Olpruva • Ravicti PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • carglumic acid • glycerol phenylbutyrate	Urea Cycle Disorder Agents

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ESTROGEN AND RELATED AGENTS			
Estrogen and Related Agents	<i>All legend generic products are preferred unless otherwise specified</i> • Angeliq • Climara Pro • Combipatch • Depo-estradiol • Evamist mist • Menest • Minivelle • Premarin • Prempro • Provera • Vivelles Dot Generic Medically Necessary PA criteria must be met for the following: • conjugated estrogens Vaginal Preparations • Estrin • Premarin Vaginal Cream • Vagifem Uterine disorder agents PA criteria must be met for the following: • Myfembree • Orlahnn • Orilissa	<i>All legend brand products are non-preferred unless otherwise specified</i> • estradiol TD gel 0.1% • ethinyl estradiol and norethindrone tabs PA criteria must be met for the following: • Lynkvet • Veozah Generic Medically Necessary PA criteria must be met for the following: • estradiol TD patch (generic formulations of Minivelle and Vivelles Dot) Vaginal Preparations • estradiol vaginal cream • Femring • Yuvaferm Generic Medically Necessary PA criteria must be met for the following: • estradiol vaginal tablets Uterine disorder agents PA criteria must be met for the following: N/A	Menopausal Symptom Suppressants Uterine Disorder Agents PA Criteria Uterine Disorder Agents PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
ESTROGEN AND RELATED AGENTS - Continued			
Contraceptives <i>Note: All contraceptive agents participating in the Medicaid Drug Rebate Program are preferred unless otherwise specified; Brand Medically Necessary PA criteria will apply to brands with available generics</i>	Injectable Contraception • Depo-SubQ Provera • medroxyprogesterone contraceptive 150mg/mL suspension for injection ○ QL – 1mL/84 days for contraception Oral/Topical Contraception • drospirenone • norethindrone • Phexxi ○ QL – 1 box/month • progestin/estrogen combinations • Twirla • Xulane Long-Acting Reversible Contraception • Kyleena ○ QL – 1 device/365 days • Liletta ○ QL – 1 device/365 days • Mirena ○ QL – 1 device/365 days • Miudella ○ QL – 1 device/365 days • Nexplanon ○ QL – 1 device/365 days • Paragard ○ QL – 1 device/365 days • Skyla ○ QL – 1 device/365 days Emergency Contraception • levonorgestrel 1.5mg • ulipristal	Injectable Contraception N/A Oral/Topical Contraception • norelgestromin/ethinyl estradiol; Zafemy ○ ST – must have previous trial of all preferred patch formulations of contraception OR medical justification for use Long-Acting Reversible Contraception N/A Emergency Contraception N/A	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
GASTROINTESTINAL AGENTS			
Anti-ulcer Agents	• misoprostol tablets • sucralfate suspension ○ ST – must be 1 year of age or older and less than 12 years of age OR unable to swallow tablets • sucralfate tablets		
H. Pylori Agents	• Pylera • Voquezna Triple Pak	• lansoprazole/amoxicillin/clarithromycin caps • Talicia • Voquezna Dual Pak Generic Medically Necessary PA criteria must be met for the following: • bismuth subcitrate/metronidazole/tetracycline	
H2 Receptor Antagonists	• cimetidine tabs ○ QL – 60/30 days • famotidine tabs ○ QL – 60/30 days • nizatidine caps ○ QL – 60/30 days	• famotidine oral suspension ○ ST – member must be under 12 years of age or unable to swallow tablets	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
GASTROINTESTINAL AGENTS - Continued			
Laxatives and Cathartics	• Linzess; lubiprostone ○ ST – requires trial of lactulose, sorbitol, or polyethylene glycol	• Ibsrela ○ ST – requires trial of lubiprostone and Linzess OR trial of lactulose, sorbitol or polyethylene glycol AND medical justification for use over preferred agents • Movantik ○ ST – requires trial of lactulose, sorbitol or polyethylene glycol AND diagnosis of opioid-induced constipation AND medical justification for use over preferred agents ○ QL – 1 tab/day • prucalopride ○ ST – requires trial of lubiprostone and Linzess OR trial of lactulose, sorbitol or polyethylene glycol AND medical justification for use over preferred agents • Symproic ○ ST – requires trial of lactulose, sorbitol or polyethylene glycol AND diagnosis of opioid-induced constipation AND medical justification for use over preferred agents ○ QL – 1 tab (0.2mg)/day	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
GASTROINTESTINAL AGENTS - Continued			
Pancreatic Enzymes <i>Note: Access will be granted to non-preferred agents after cumulatively utilizing 30 days of preferred agent therapy in the past 180 days</i>	- Creon - Zenpep	- Pertzye - Viokace	
Proton Pump Inhibitors <i>Note: PA is required for members utilizing therapy for greater than 90 days in a 180-day period.</i>	<i>See Proton Pump Inhibitors PA Criteria for product-specific quantity limits</i> - Dexilant - esomeprazole capsules - lansoprazole capsules - omeprazole capsules - pantoprazole tablets IV Solutions N/A Oral Solutions - Nexium packets - Protonix packets	<i>See Proton Pump Inhibitors PA Criteria for product-specific quantity limits, step therapy, and criteria to access non-preferred agents</i> PA criteria must be met for the following: - omeprazole magnesium/sodium bicarbonate caps - rabeprazole Generic Medically Necessary PA criteria must be met for the following: - dexlansoprazole IV Solutions PA criteria must be met for the following: - esomeprazole IV - pantoprazole IV Oral Solutions PA criteria must be met for the following: - Konvomep oral suspension - lansoprazole ODT - omeprazole/sodium bicarb powder - Prilosec packets Generic Medically Necessary PA criteria must be met for the following: - esomeprazole packets - pantoprazole packets	Proton Pump Inhibitor PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
GASTROINTESTINAL AGENTS - Continued			
Ulcerative Colitis Agents	Oral Formulations • Azulfidine/Azulfidine EN • balsalazide • budesonide DR caps • Dipentum • mesalamine DR cap • mesalamine DR (Lialda) tab • mesalamine ER (Apriso) cap • mesalamine 250 mg ER (generic Pentasa) cap • Pentasa Rectal Formulations • mesalamine enema • mesalamine suppositories • sfRowasa	Oral Formulations • budesonide ER tabs • mesalamine DR (Asacol HD) tabs Generic Medically Necessary PA criteria must be met for the following: • mesalamine ER 500 mg (Pentasa) cap • sulfasalazine IR/DR Rectal Formulations • budesonide rectal foam	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
GENITOURINARY			
BPH Agents	• alfuzosin ER • dutasteride • finasteride • tamsulosin	• dutasteride/tamsulosin ○ ST – must provide documentation that separate components are not suitable for use • silodosin ○ ST – requires trial of alfuzosin ER and tamsulosin OR medical justification for use of silodosin over alfuzosin ER and tamsulosin • tadalafil 2.5mg and 5mg ○ ST – prescriber must provide documentation of trial and failure of nonselective alpha-blocker, a selective alpha-blocker, a 5-alpha reductase inhibitor, and a combination product for the treatment of BPH or a medically justifiable reason that the agents are not suitable for use; therapy duration must not exceed 26 weeks if using concurrently with finasteride	
Urinary Tract Antispasmodic/Anti-Incontinence Agents	• bethanechol • fesoterodine ER • Myrbetriq tablets • oxybutynin IR • oxybutynin ER • Oxytrol • Solifenacin • tolterodine IR • tolterodine ER	• darifenacin • flavoxate • Gemtesa ○ ST – member must have trialed and failed Myrbetriq or prescriber has provided medical justification for the use of Gemtesa (vibegron) over Myrbetriq (mirabegron) • Myrbetriq granules ○ ST – must be 3 years of age or older and less than 12 years of age OR unable to swallow tablets • trospium • trospium ER • Vesicare LS ○ ST – must be 2 years of age or older and less than 12 years of age OR unable to swallow tablets Generic Medically Necessary PA criteria must be met for the following: • mirabegron granules/tablets	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
HEMATOLOGIC			
Direct Oral Anticoagulants	- dabigatran capsules - Eliquis - QL – 2 tabs/day of 2.5mg; 4 tabs/day for 7 days, then 2 tabs/day for 5mg - Eliquis soluble tablet - QL – up to 32 tabs/day for 7 days; then up to 16 tabs/day - ST – member is less than 18 years of age and weighs 4 kg to less than 35 kg - Eliquis sprinkle capsule - QL – 4 caps/day for 7 days; then 2 caps/day - ST – member is less than 18 years of age and weighs 2.6 kg to less than 4 kg - Eliquis Starter Pack - QL – 1 pack/90 days - rivaroxaban 2.5mg tablets - QL – 2 tabs/day - Xarelto 10mg tablets - QL – 1 tab/day - Xarelto 15 mg tablets - QL – 2 tabs/day for max 21 consecutive days every 90 days; no duration restriction for once-daily dosing - Xarelto 20 mg tablets - QL – 1 tab/day - Xarelto Starter Kit - QL – 1 starter kit/90 days - Xarelto suspension - ST – must be under 12-years of age or unable to swallow tablets - QL – 20 mg/day (20 mL/day)	- Pradaxa Pak - ST – must be under 8 years of age or unable to swallow capsules OR have medical rationale for use of pellet formulation - Savaysa - QL – 1 tab/day - ST – must have trialed Eliquis and Xarelto OR medical justification for use of Savaysa over Eliquis and Xarelto Generic Medically Necessary PA criteria must be met for the following: - rivaroxaban suspension	
Hematinics	<i>Erythropoiesis-Stimulating Agents</i> PA criteria must be met for the following: - Aranesp - Epogen - Retacrit <i>Miscellaneous Hematinics</i> - N/A	<i>Erythropoiesis-Stimulating Agents</i> PA criteria must be met for the following: - Mircera - Procrit <i>Miscellaneous Hematinics</i> PA criteria must be met for the following: - Reblozyl	Hematinic Agents PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
HEMATOLOGIC - Continued			
Hemophilia Prophylaxis Agents	Hemlibra	PA criteria must be met for the following: - Alhemo - Hypavzi - Qfitlia	Hemophilia Prophylaxis Agents PA
Hereditary Angioedema Agents	- Cinryze - Orladeyo - Takhzyro	- Andembry - Dawnzera - Haegarda	
Leukocyte Stimulants	Short-Acting - Neupogen - Releuko Long-Acting - Fulphila - Fylnetra	Short-Acting - Granix - Leukine - ST – trial and failure of all preferred short-acting agents OR Leukine (sargramostim) is being used in combination with an antineoplastic monoclonal antibody (e.g., dinutuximab, naxitamab) that requires concurrent use - Nivestym - Nypozi - Zarxio Long-Acting - Neulasta - Neulasta Onpro - Nyvepria - Rolvedon - Ryzneuta - Stimufend - Udenyca - Udenyca Onbody - Ziextenzo	
Platelet Aggregation Inhibitors	- aspirin/dipyridamole - ticagrelor - QL – 2 tabs/day - cilostazol - clopidogrel 75 mg - clopidogrel 300 mg tablets - QL – 1 tab/Rx - prasugrel		

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
LIPOTROPICS			
Bile Acid Sequestrants	- cholestyramine multi-dose containers - colesevelam tablets and suspension - Prevalite powder/packets	- cholestyramine packets - Colestid granules/tablet Generic Medically Necessary PA criteria must be met for the following: - colestipol (granules/tablets)	
Fibric Acid Derivatives	- fenofibrate micronized cap (generic Antara) - fenofibrate micronized cap (generic Lofibra) - fenofibrate tab (generic Tricor) - gemfibrozil	- fenofibrate cap - fenofibric acid cap (generic Trilipix) - fenofibric acid tab - fenofibrate tab (generic Fenoglide) - Lipofen	
HMG CoA Reductase Inhibitors	- Atorvaliq - ST – must be 10 years of age or older and less than 12 years of age OR 12 years of age or older and unable to swallow tablets - atorvastatin - lovastatin - pravastatin - rosuvastatin - simvastatin	- Altoprev - Ezallor - fluvastatin - fluvastatin ER - pitavastatin	
Lipotropics	- ezetimibe - ezetimibe/simvastatin - ST – must have trial history of a single-agent HMG CoA reductase inhibitor for 90 of the past 120 days - omega-3-acid ethyl esters - icosapent ethyl - Age – 18 years of age or older - QL – 4 capsules/day PA criteria must be met for the following: - Repatha	- Nexletol - ST – must have trialed and failed two statin agents OR a statin in combination with ezetimibe OR medical justification for use over preferred statins and ezetimibe - Nexlizet - ST – must have trialed and failed a statin in combination with ezetimibe OR medical justification for use over preferred statins and ezetimibe PA criteria must be met for the following: - Evkeeza - Juxtapid - Leqvio - niacin ER - Praluent - Redemplo - Tryngolza	PCSK9 Inhibitors and Select Lipotropics PA Criteria PCSK9 Inhibitors and Select Lipotropics PA Form

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
MULTIPLE SCLEROSIS AGENTS			
Multiple Sclerosis Agents	PSQC/PA criteria must be met for the following: • Avonex • Betaseron • Briumvi • Copaxone 20 mg/mL • dalfampridine • dimethyl fumarate • fingolimod 0.5 mg • Gilenya 0.25 mg • glatiramer 40 mg/mL • Glatopa 40 mg/mL • Kesimpta • Ocrevus; Ocrevus Zunovo • Rebif • teriflunomide • Tascenso ODT • Tysabri • Zeposia	PSQC/PA criteria must be met for the following: • Bafiertam • Lemtrada • Mavenclad • Mayzent • Plegridy • Ponvory • Tyruko • Vumerity PSQC/PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • cladribine • glatiramer 20 mg/mL • Glatopa 20 mg/mL	Multiple Sclerosis PA with Quantity Limits Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
RESPIRATORY			
Antihistamine-Decongestant Combinations/2 nd Generation Antihistamines	- cetirizine 5 mg OTC tabs - AGE – under 18 years - cetirizine 10 mg OTC tabs - fexofenadine OTC tabs - levocetirizine Rx tabs - loratadine 10 mg OTC tabs - loratadine 10 mg OTC RDT tabs Combinations - loratadine/pseudoephedrine 12-hour OTC tabs - QL – 2 tablets/day - ST – previous trial and failure of a preferred single-agent 2nd generation antihistamine - loratadine/pseudoephedrine 24-hour OTC tabs - QL – 1 tablet/day - ST – previous trial and failure of a preferred single-agent 2nd generation antihistamine Liquid Formulation - cetirizine 1 mg/ml OTC syrup and Rx syrup; loratadine 1 mg/mL OTC syrup - AGE – under 12 years or unable to swallow tablet formulation, max age 18 years - QL – 10 mL/day - fexofenadine 30 mg/5 mL OTC susp - AGE – under 12 years or unable to swallow tablet formulation, max age 18 years - QL – 30 mL/day - ST – must have trial of both cetirizine solution (Rx or OTC) and loratadine solution (OTIC) within the past 90 days - levocetirizine Rx oral soln - QL – 10 mL/day - ST – must have trial of both cetirizine solution (Rx or OTC) and loratadine soln (OTC) within the past 90 days	Note: New patients must first try cetirizine and loratadine within 90 days prior to receiving a non-preferred agent. Patients with an existing PA are not subject to the step edit. - desloratadine Rx tabs - desloratadine Rx ODT tabs Combinations - Clarinet-D Rx tabs - QL – 2 tablets/day - ST – previous trial and failure of loratadine/pseudoephedrine 12-hour OTC tab Liquid Formulation - desloratadine 0.5 mg/mL solution - QL – 10 mL/day - ST – must have trial on both cetirizine and loratadine within the past 90 days	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
RESPIRATORY - Continued			
Beta Adrenergics and Corticosteroids <i>Note: All agents are limited to 1 diskus or inhaler per month unless otherwise specified</i>	- Advair Diskus 100/50 mcg, 250/50 mcg, 500/50 mcg - Advair HFA 45/21 mcg, 115/21 mcg, 230/21 mcg - Breztri Aerosphere - Asthma ST – must have tried and failed a beta adrenergic/corticosteroid combination inhaler for at least 90 days of the past 120 days - COPD ST – must have tried and failed Anoro Ellipta therapy for at least 90 of the past 120 days - Dulera 200-5 mcg QL of 3 units per 30 days for ages 19 and younger/2 units per 30 days for ages 20 and over apply to the following: - Dulera 50-5 mcg, 100-5 mcg - Symbicort 80-4.5 mcg, 160-4.5 mcg	- Airsupra - AGE – 18 years of age and older - QL – 2 inhalers per 30 days - ST – trial and failure of Dulera or Symbicort as reliever therapy (supported by chart documentation) - Breo Ellipta - fluticasone/salmeterol Respiclick (Airduo Respiclick ABA) 55-13 mcg, 113-14 mcg, 232-14 mcg - Trelegy Ellipta - Asthma ST – must have tried and failed a beta adrenergic/corticosteroid combination inhaler for at least 90 days of the past 120 days - COPD ST – must have tried and failed Anoro Ellipta therapy for at least 90 of the past 120 days - Wixela Generic Medically Necessary PA criteria must be met for the following: - fluticasone/salmeterol (generic Advair Diskus) 100/50 mcg, 250/50 mcg, 500/50 mcg - fluticasone/salmeterol HFA (Advair HFA ABA) 45-21 mcg, 115-21 mcg, 230-21 mcg - fluticasone/vilanterol (Breo Ellipta ABA) Generic Medically Necessary PA criteria apply to the following: - budesonide/formoterol 80-4.5 mcg, 160-4.5 mcg - Breyna	
Beta Agonists – Long Acting	Serevent	- arformoterol - formoterol - Striverdi Respimat	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
RESPIRATORY - Continued			
Beta Agonists – Short Acting	- albuterol nebs/syrup – (all strengths) QL of 3 canisters per 30 days for ages 18 and younger/2 canisters per 30 days for ages 19 and over apply to the following: - Ventolin HFA - Xopenex HFA - ST – must have tried an albuterol HFA inhaler in the past 90 days	- albuterol tablets (brand/generic) - levalbuterol neb soln - QL – 2 prescriptions per 180 days, 1 box of 25 per prescription - terbutaline tablets QL of 3 canisters per 30 days for ages 18 and younger/2 canisters per 30 days for ages 19 and over apply to the following: - albuterol HFA - levalbuterol HFA (must also meet generic medically necessary PA criteria) - Proair Respiclick	
Bronchodilator Agents-Beta Adrenergic and Anticholinergic Combinations <i>Note: Must not concurrently use >1 inhaled anticholinergic agent (excluding short-acting nebulization solution)</i>	Short-Acting - Atrovent HFA - QL – 2 inhalers/30 days - Combivent Respimat - QL – 2 inhalers/30 days - ipratropium soln - QL – 2 boxes/30 days - ipratropium/albuterol soln - QL – 3 boxes/30 days Long-Acting - Spiriva Handihaler - QL – 1 inhaler/30 days - Anoro Ellipta - QL – 1 inhaler/30 days - Incruse Ellipta - QL – 1 inhaler/30 days - Spiriva Respimat 1.25 mcg - QL – 1 inhaler/30 days - Spiriva Respimat 2.5 mcg - QL – 1 inhaler/30 days	Short-Acting Generic Medically Necessary PA criteria must be met for the following: - ipratropium HFA Long-Acting - Bevespi Aerosphere - QL – 1 inhaler/30 days - Duaklir Pressair - QL – 1 inhaler/30 days - Stiolto Respimat - QL – 1 box (60 inhalations)/30 days - Tudorza Pressair - QL – 1 inhaler/30 days - Yupelri - QL – 1 box (90mL)/30 days Generic Medically Necessary PA criteria must be met for the following: - tiotropium inhalation capsules - umeclidinium - umeclidinium/vilanterol (Anoro Ellipta ABA)	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
RESPIRATORY - Continued			
Leukotriene Receptor Antagonists	montelukast	- montelukast granules - ST – must have prescriber documentation indicating tablet formulations are unsuitable for use - zafirlukast - zileuton SR 12 HR - Zyflo	
Nasal Antihistamines/Nasal Anti-Inflammatory Steroids	Antihistamines/Anticholinergics - azelastine 0.1% nasal spray - ipratropium NS Steroids/Steroid Combinations - Dymista - fluticasone - Omnaris	Antihistamines/Anticholinergics - azelastine 0.15% nasal spray - olopatadine Steroids/Steroid Combinations - budesonide nasal suspension - flunisolide - mometasone nasal susp - Qnasl - Ryaltris Generic Medically Necessary PA criteria must be met for the following: - azelastine/fluticasone nasal spray	
Oral Inhaled Glucocorticoids	- Arnuity Ellipta - QL – 1 inhaler/30days - Asmanex, Asmanex HFA - QL – 1 inhaler/30days - budesonide inhalation suspension - AGE – 3 years and younger - QL – 120 mL/30 days (0.25 mg/2 mL vial, 0.5 mg/2 mL vial); 60 mL/30 days (1 mg/2 mL vial) - fluticasone propionate HFA - fluticasone Diskus - Pulmicort Flexhaler - QVAR Redihaler	- Alvesco - beclomethasone dipropionate HFA - QL – 2 inhalers/30 days - budesonide inhalation suspension - AGE – 4 years and older - QL – 120 mL/30 days (0.25 mg/2 mL vial, 0.5 mg/2 mL vial); 60 mL/30 days (1 mg/2 mL vial) Generic Medically Necessary PA criteria must be met for the following: - fluticasone (Arnuity Ellipta ABA) - QL – 1 inhaler/30 days	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
RESPIRATORY - Continued			
Pulmonary Antihypertensives	PSQC/PA criteria must be met for the following: • Alyq • bosentan IR tablet/dispersible tablet • sildenafil inj/susp/tab • tadalafil • Tadliq	PSQC/PA criteria must be met for the following: • Adempas • ambrisentan • macitentan • Opsynvi • Orenitram. Orenitram Titration Pack • Tyvaso, Tyvaso DPI • Uptravi • Winrevair • Yutrepia	Pulmonary Antihypertensives PA Criteria Pulmonary Antihypertensives PA Form
Respiratory and Allergy Biologics	PSQC/PA criteria must be met for the following: • Dupixent • Fasenra • Nucala • Omlyclo • Tezspire • Xolair	PSQC/PA criteria must be met for the following: • Cinqair • Exdensur	Respiratory and Allergy Biologics PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)	
TARGETED IMMUNOMODULATORS				
Targeted Immunomodulators	PSQC/PA criteria must be met for the following: - adalimumab products - adalimumab-adaz - Hadlima - Adbry - Cimzia - Ebglyss - Enbrel - Entyvio, Entyvio Pen - infliximab products - Avsola - infliximab (unbranded Remicade) - Kevzara - Kineret - Litfulo - Olumiant - Orencia vials & syringes - Otezla; Otezla XR - Rinvoq - Rinvoq LQ - Simponi, Simponi Aria - Taltz - tocilizumab products - Tyenne - Tremfya - ustekinumab products - Pyzchiva - Starjemza - Xeljanz - Xeljanz oral soln - ST - the member is 2 years of age or older and weighing 10 kg or more AND less than 18 years of age and weighing less than 40 kg, OR provider has submitted documentation supporting inability to swallow tablet formulation - tofacitinib ER	PSQC/PA criteria must be met for the following: - adalimumab products - Abrilada - adalimumab-aacf - adalimumab-aaty - adalimumab-adbm - adalimumab-fkjp - adalimumab-ryvk - Amjevita - Cyltezo - Hulio - Humira - Hyrimoz - Idacio - Simlandi - Yuflyma - Yusimry - Arcalyst - Bimzelx - Cibinqo - Cosentyx - Icotyde - Ilaris - Ilumya - infliximab products - Inflectra - Remicade - Renflexis - Zymfentra Generic Medically Necessary PA criteria must be met for the following: - tofacitinib - tofacitinib solution	- Leqselvi - Nemludio - Omvoth - Rhapsido - Skyrizi - Sotyktu - Spevigo - tocilizumab products - Actemra - Avtozma - Tofidence - ustekinumab products - Imuldosa - Otulfi - Selarsdi - Stelara - Steqeyma - ustekinumab - ustekinumab-aaaz - ustekinumab-aekn - ustekinumab-ttwe - Yesintek - Velsipity	Targeted Immunomodulators PA Criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
TOPICAL AGENTS			
Dry Eye Disease or Keratoconjunctivitis <i>See Dry Eye Disease or Keratoconjunctivitis PA Criteria for product-specific quantity limits</i> <i>*Note: No more than a 30-day supply may be dispensed at one time.</i>	PSQC/PA criteria must be met for the following: - Restasis single dose - Xiidra	PA criteria must be met for the following: - Cequa - Eysuvis - Miebo - Restasis Multidose - Tryptyr - Tyrvaya - Verkazia - Vevye Generic Medically Necessary PA criteria must be met for the following: - cyclosporine single dose emulsion	Dry Eye Disease of Keratoconjunctivitis PA criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
TOPICAL AGENTS - Continued			
Miotics-Intraocular Pressure Reducers	• Alphagan-P 0.1% • Alphagan-P 0.15% • apraclonidine • Azopt • Betoptic-S • brimonidine 0.2% soln • carteolol • Combigan • dorzolamide • dorzolamide/timolol • Iopidine 1% • latanoprost • levobunolol • Lumigan 0.01% drops • pilocarpine 1%, 2%, 4% soln • Rhopressa • Rocklatan • Simbrinza • timolol maleate soln • Travatan Z	• Betaxolol • Betimol • bimatoprost 0.03% • Cosopt PF • Iyuzeh ○ ST – must have tried and failed latanoprost OR prescriber has provided medical justification for use of Iyuzeh over latanoprost • timolol gel • Vyzulta • Xelpros • Zioptan PA criteria must be met for the following: • Vuity Generic Medically Necessary PA criteria must be met for the following: • bimatoprost 0.01% • brimonidine 0.1% soln • brimonidine 0.15% soln • brimonidine/timolol soln • brinzolamide suspension • tafluprost • timolol hemihydrate soln • travoprost 0.004% PA criteria AND Generic Medically Necessary PA criteria must be met for the following: • pilocarpine 1.25% soln	Presbyopia Agents PA criteria

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
TOPICAL AGENTS - Continued			
Ophthalmic Antihistamines	- Alaway - azelastine - Bepreve - ketotifen	- epinastine - Zerviate Generic Medically Necessary PA criteria must be met for the following: - bepotastine besilate	
Ophthalmic Anti-Inflammatory Agents	NSAIDs - diclofenac 0.1% ophth soln - flurbiprofen 0.3% ophth soln - ketorolac 0.4% ophth soln - ketorolac 0.5% ophth soln - Nevanac 0.1% ophth soln - Prolensa 0.07% ophth soln Steroids - Alrex 0.2% ophth susp - dexamethasone sod phos 0.1% ophth soln - Durezol 0.05% ophth emul - Flarex 0.1% ophth susp - FML Liquifilm 0.1% ophth susp - Lotemax 0.5% ophth gel/ointment - loteprednol 0.5% ophth susp - prednisolone acetate 1% ophth susp - Pred Mild 0.12% ophth susp - prednisolone sod phos 1% ophth soln	NSAIDs - Acuvail 0.45% ophth soln - bromfenac 0.075% ophth soln - bromfenac 0.09% ophth soln - Ilevro 0.3% ophth soln Generic Medically Necessary PA criteria must be met for the following: - bromfenac 0.07% ophth soln Steroids - FML Forte 0.25% ophth susp - Inveltys 1% ophth susp - Lotemax SM 0.38% ophth gel - Maxidex 0.1% ophth susp Generic Medically Necessary PA criteria must be met for the following: - difluprednate 0.05% ophth emul - fluorometholone 0.1% ophth susp - loteprednol 0.2% ophth susp - loteprednol 0.5% ophth gel	
Otic Preparations	- acetic acid soln - fluocinolone acetonide oil	acetic acid HC	

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

DRUG CLASS	PREFERRED	NON-PREFERRED	PA CRITERIA (if applicable)
TOPICAL AGENTS - Continued			
Topical Anti-Inflammatory Agents – NSAIDS	- diclofenac 1% gel - diclofenac 2% topical soln	- diclofenac epolamine patch - QL – 2 patches per day - ST – requires physician documentation indicating oral medications are unsuitable for use AND trial and failure of diclofenac 1% gel and diclofenac 2% topical solution, OR medical justification for use over preferred agents	
Topical Antiparasitics <i>Unless otherwise specified, all products are limited to one bottle or one tube per claim</i>	- Natroba - permethrin 5% cream - permethrin 1% lotion - spinosad	- Crotan - ivermectin lotion - Malathion - Pruradik - VanaLice	
Topical Immunomodulators	PA criteria must be met for the following: - Eucrisa - Opzelura - pimecrolimus cream - tacrolimus ointment - Vtama	PA criteria must be met for the following: - Anzupgo - Zoryve 0.05% cream - Zoryve 0.15% cream - Zoryve 0.3% cream - Zoryve 0.3% foam	Topical Immunomodulators PA criteria
Topical Post-Herpetic Neuralgia Agents	- lidocaine patches - QL – 3 boxes/30 days - Lidoderm - QL – 3 boxes/30 days	- Lidotral - QL – 3 boxes/30 days - Qutenza - QL – 4 patches/3 months - ST – must have tried lidocaine patches and over-the-counter capsaicin cream - ZTlido - QL – 3 boxes/30 days - ST – must have previous trial of at least 30 days of therapy with preferred lidocaine 5% patches	

MISCELLANEOUS INFORMATION	
Brand Medically Necessary/Generic Medically Necessary Prior Authorization Form IHCP Early Refill Prior Authorization Request Form Mental Health Medications Medical Necessity Prior Authorization Form Non-Drug-Specific PA Criteria OTC Contraceptive Agents Formulary OTC Drug Formulary OTC Pharmacy Supplements Formulary	PBM Call Center LTC ProDUR and Home Health PA Request Form PBM Call Center Prior Authorization Form Preferred Brand Drug List Utilization Edits for Mental Health Medications Vaccine Utilization Edits Vaccine Utilization Edits for VFC-Enrolled Pharmacies

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.

MISCELLANEOUS INFORMATION - Continued

[Allergy Specific Immunotherapy PA Criteria](#)

[Amyloid Beta-Directed Antibodies](#)

[Aromatase Inhibitors PA Criteria](#)

[Complement Inhibitor Agents PA](#)

[Corticotropin](#)

[Cushing Syndrome Agents](#)

[Cushing Syndrome Agents PA Form](#)

[Cystic Fibrosis Inhaled Agents PA Criteria](#)

[Cystic Fibrosis Agents PA Criteria](#)

[Cystic Fibrosis Agents PA Form](#)

[Daybue PA Criteria](#)

[Disposable Insulin Delivery Devices PA](#)

[Egrifta PA Criteria](#)

[Elevidys PA Criteria](#)

[Elmiron PA Criteria](#)

[Epidermolysis Bullosa Agents PA](#)

[Gaucher Disease PA Criteria](#)

[Gralise, Horizant, and Lyrica CR PA Criteria](#)

[Gralise, Horizant, and Lyrica CR PA Form](#)

[HCG PA Criteria](#)

[Hemophilia B Gene Therapy PA](#)

[Hepatitis B Agents PA Criteria](#)

[High Dollar Compounded PA Criteria](#)

[High Dollar Compounded PA Request Form](#)

[Immunoglobulin A Nephropathy \(IgAN\) Agents PA](#)

[Intravesical Immunotherapy PA](#)

[Lucemyra PA Criteria](#)

[Lucemyra PA Form](#)

[MASH/MASLD Agents](#)

[Mepron PA Criteria](#)

[Metabolic Disorders PA](#)

[Muscular Dystrophy Agents PA Criteria](#)

[Muscular Dystrophy Agents PA Form](#)

[Nephrotic Cystinosis PA Criteria](#)

[Niemann-Pick Disease Agents PA Criteria](#)

[Non-SUPDL Agents PA and ST](#)

[Nuedexta PA Criteria](#)

[Nuedexta PA Form](#)

[Oxervate PA Criteria](#)

[Phenylketonuria Agents PA](#)

[Phosphodiesterase Inhibitors for Pulmonary Related Disorders](#)

[Phosphodiesterase Inhibitors for Pulmonary Related Disorders PA Form](#)

[Pompe Disease Agents PA Criteria](#)

[Prenatal Vitamins High Dollar Limit PA](#)

[Roctavian PA Criteria](#)

[Sickle Cell Agents PA Criteria](#)

[Sickle Cell Agents PA Form](#)

[Skyclarys PA criteria](#)

[Solaraze PA Criteria](#)

[Somatostatin Analog PA Criteria](#)

[Spinal Muscular Atrophy Agents PA Criteria](#)

[Spinal Muscular Atrophy Agents PA Form](#)

[Thrombopoietin and Related Conditions PA](#)

[Topical Doxepin PA](#)

[Topical Lidocaine QL](#)

[Topical Steroid PA](#)

[Topical Agents PA Form](#)

[Transthyretin Impacting Agents PA Criteria](#)

[Tzield PA](#)

[Tzield PA Form](#)

[Vykat XR PA](#)

[Yorvipath PA criteria](#)

[Zycubo PA](#)

Effective for FFS and Managed Care Organization claims submitted on or after October 1, 2026. V1.0

Inclusion or reference to any given drug does not indicate market availability of the drug. Drugs that will be, or have been, withdrawn from the market will be removed from the SUPDL as part of routine periodic updating of the SUPDL.